General Information of This Target
Target ID
PATR0RIOXT
Target Name
Human deoxyribonucleic acid (hDNA)
Function
Deoxyribonucleic acid (DNA) is a polymer composed of two polynucleotide chains that coil around each other to form a double helix. The polymer carries genetic instructions for the development, functioning, growth and reproduction of all known organisms and many viruses. DNA and ribonucleic acid (RNA) are nucleic acids.

    Click to Show/Hide
Full List of The ADC Related to This Target
Approved in 2021
Click To Hide/Show 3 ADC Related to This Stage
ADC Info ADC Name Antibody Antigen Payload Linker Ref
Loncastuximab tesirine
Loncastuximab
CD19
SG3199 (SC-DR002)
Mal-PEG8-Val-Ala-PABC
Inotuzumab ozogamicin
Inotuzumab
CD22
N-acetyl-gamma-calicheamicin
AcButDMH
[1]
Gemtuzumab ozogamicin
Gemtuzumab
CD33
N-acetyl-gamma-calicheamicin
AcButDMH
[2]
New Drug Application (discontinued)
Click To Hide/Show 1 ADC Related to This Stage
ADC Info ADC Name Antibody Antigen Payload Linker Ref
Trastuzumab duocarmazine
Trastuzumab
HER2
Seco-DUBA
Mal-PEG2-Val-Cit-PABA-Cyclization Spacer
Phase 3 (discontinued)
Click To Hide/Show 2 ADC Related to This Stage
ADC Info ADC Name Antibody Antigen Payload Linker Ref
Rovalpituzumab tesirine
Rovalpituzumab
DLL3
SG3199 (SC-DR002)
Mal-PEG8-Val-Ala-PABC
Vadastuximab talirine
Vadastuximab
CD33
SGD-1882
Mc-Val-Ala
Phase 2 (discontinued)
Click To Hide/Show 2 ADC Related to This Stage
ADC Info ADC Name Antibody Antigen Payload Linker Ref
Camidanlumab tesirine
Camidanlumab
CD25
SG3199 (SC-DR002)
Mal-PEG8-Val-Ala-PABC
Vobramitamab duocarmazine
Vobramitamab
B7-H3
seco-DUBA
Mal-PEG2-Val-Cit-PABA-Cyclization Spacer
Phase 2 (discontinued)
Click To Hide/Show 1 ADC Related to This Stage
ADC Info ADC Name Antibody Antigen Payload Linker Ref
CMB-401
HCTM01
Muc1
N-acetyl-gamma-calicheamicin
Amide-based linker
Apprpved in 2026
Click To Hide/Show 2 ADC Related to This Stage
ADC Info ADC Name Antibody Antigen Payload Linker Ref
Pivekimab sunirine
Pivekimab
CD123
DGN549
Mal-adipamide-Ala-Ala
Epratuzumab-cys-tesirine
Epratuzumab
CD22
SG3199 (SC-DR002)
Mal-PEG8-Val-Ala-PABC
Phase 1
Click To Hide/Show 9 ADC Related to This Stage
ADC Info ADC Name Antibody Antigen Payload Linker Ref
BYON3521
SYD2884
c-Met
Seco-DUBA
Mal-PEG2-Val-Cit-PABA-Cyclization Spacer
DS-9606a
Anti-CLDN6 antibody
CLDN6
PBD dimer
A cleavable linker
LCB73
Anti-CD19 antibody
CD19
PBD dimer
β-glucuronide trigger linker
ABL202
Anti-ROR1 IgG1 mAb
ROR1
PBD dimer
β-glucuronide trigger linker
Mipasetamab uzoptirine
Mipasetamab
Axl
SG3199 (SC-DR002)
BCN-HydraSpace-Val-Ala-PABC
MT-8633
HD12
c-Met
SG3199 (SC-DR002)
Mal-PEG8-Val-Ala-PABC
BYON-4413
Anti-CD123 IgG1 mAb
CD123
Seco-DUBA
Mal-PEG2-Val-Cit-PABA-Cyclization Spacer
ADCT-701
HuBa-1-3D
DLK1
SG3199 (SC-DR002)
BCN-HydraSpace-Val-Ala-PABC
Olintatug tesirine
Olintatug
KAAG1
SG3199 (SC-DR002)
Mal-PEG8-Val-Ala-PABC
Phase 1 (discontinued)
Click To Hide/Show 25 ADC Related to This Stage
ADC Info ADC Name Antibody Antigen Payload Linker Ref
MEDI2228
BCMA-Ab1
BCMA
SG3199 (SC-DR002)
Mal-PEG8-Val-Ala-PABC
MEDI3726
J591
PSMA
SG3199 (SC-DR002)
Mal-PEG8-Val-Ala-PABC
Rolinsatamab talirine
Rolinsatamab
PRLR
SGD-1882
Mc-Val-Ala
SC-002
Rovalpituzumab
DLL3
SG3199 (SC-DR002)
Val-Ala dipeptide linker
SC-006
Anti-RNF43 antibody
RNF43
SG3312 (SC-DR003)
Mc-Val-Ala
ABBV-011
SC17
SEZ6
N-acetyl-gamma-calicheamicin
Mc-PEG8-acid-labile linker
Serclutamab talirine
Serclutamab
EGFR
SGD-1882
Mc-Val-Ala
SYD1875
SYD1594
5T4
Seco-DUBA
Mal-PEG2-Val-Cit-PABA-Cyclization Spacer
TAK-164
5F9
GC-C
DGN549
Mal-adipamide-Ala-Ala
Tamrintamab pamozirine
Tamrintamab
DPEP3
SG3199 (SC-DR002)
Mc-Val-Ala-PABC
ADCT-502
Trastuzumab variant
HER2
SG3199 (SC-DR002)
Mal-PEG8-Val-Ala-PABC
CMD-193
G193
Lewis Y
N-acetyl-gamma-calicheamicin
AcButDMH
PF-06647263
HuE22
EFNA4
N-acetyl-gamma-calicheamicin
AcButDMH
RG6148
MHES0488A
HER2
PBD dimer
Cleavable disulfide linker
SC-007
undisclosed
Undisclosed
PBD dimer
Undisclosed
SGN-CD123A
H7G3ec
CD123
SGD-1882
Mc-Val-Ala
SGN-CD19B
HBU12ec
CD19
SGD-1882
Mc-Val-Ala
SGN-CD352A
H20F3ec
SLAMF6
PBD dimer
Val-Ala dipeptide linker
SGN-CD70A
H1F6ec
CD70
PBD dimer
dipeptide linker
SC-004
An antibody targeting CLDN6/9
CLDN6; CLDN9
SGD-1882
Val-Cit linker
BMS-936561
MDX-1115
CD70
Seco-MED-A
Mal-Val-Cit
IMGN779
Z4681A
CD33
DGN462
Sulfo-SPDB
RG6109
MCLL0517A
CLL-1
PBD dimer
Cleavable disulfide linker
SC-005
undisclosed
Undisclosed
PBD dimer
Undisclosed
[3]
MEDI7247
Idactamab
ASCT2
SG3199 (SC-DR002)
Mal-PEG8-Val-Ala-PABC
Investigative
Click To Hide/Show 665 ADC Related to This Stage
ADC Info ADC Name Antibody Antigen Payload Linker Ref
111In-1849
Anti-TF mAb 1849
Tissue factor (F3)
Indium-111
Undisclosed
[4]
111In-DOTA-5D3
Anti-PSMA mAb 5D3
Glutamate carboxypeptidase 2 (FOLH1)
Indium-111
Tetraxetan
[5]
T-PBA
Trastuzumab
Receptor tyrosine-protein kinase erbB-2 (ERBB2)
PBD-based payload 37b3
Mc-Val-Ala
[6]
WO2021044208A1 ADC A2F2 M1-6
Anti-ROR1 mAb A2F2 M1
Inactive tyrosine-protein kinase transmembrane receptor ROR1 (ROR1)
SG2000
WO2021044208A1_ADC A2F2 M1-6 linker
[7]
WO2021044208A1 ADC A2F2 M1-6
Anti-ROR1 mAb A2F2 M1
Inactive tyrosine-protein kinase transmembrane receptor ROR1 (ROR1)
SG2000
WO2021044208A1_ADC A2F2 M1-7 linker
[7]
Trastuzumab-Flexmab-SG3710
Trastuzumab-Flexmab
Receptor tyrosine-protein kinase erbB-2 (ERBB2)
SG3199
Mal-PEG8-Val-Ala-PABC
[8]
Trastuzumab-C239I-SG3249
Trastuzumab
Receptor tyrosine-protein kinase erbB-2 (ERBB2)
SG3199
Mal-PEG8-Val-Ala-PABC
[8]
Trastuzumab-C239I-SG3600
Engineered trastuzumab
Receptor tyrosine-protein kinase erbB-2 (ERBB2)
N10-beta-glucuronide SG3200
Mal-PEG8-Val-Ala-PABC
[9]
Trastuzumab-C239I-SG3400
Engineered trastuzumab
Receptor tyrosine-protein kinase erbB-2 (ERBB2)
SG3200
Mal-PEG8-Val-Ala-PABC
[9]
Fv-LDP-D3-AE
Fv-LDP-D3
Epidermal growth factor receptor (EGFR)
Lidamycin
Undisclosed
[10]
Cetuximab- (FGX16-11)
Cetuximab
Epidermal growth factor receptor (EGFR)
FGX8-46
Mc-Val-Ala-PABC
[11]
D3-GPC2-PBD
Fully human D3-GPC2-IgG1
Glypican-2 (GPC2)
PBD dimer
Undisclosed
[12]
Trastuzumab-SG3227
Trastuzumab
Receptor tyrosine-protein kinase erbB-2 (ERBB2)
SG2219
Acetamide-PEG4-Val-Ala-PABA
[13]
Engineered HER-SG3227
Engineered trastuzumab
Receptor tyrosine-protein kinase erbB-2 (ERBB2)
SG2219
Acetamide-PEG4-Val-Ala-PABA
[13]
HER-SG3249
Trastuzumab
Receptor tyrosine-protein kinase erbB-2 (ERBB2)
SG3199
Mal-PEG8-Val-Ala-PABC
[14]
Site-specific HER-SG3249
Trastuzumab
Receptor tyrosine-protein kinase erbB-2 (ERBB2)
SG3199
Mal-PEG8-Val-Ala-PABC
[14]
Trastuzumab-SG3600 high DAR
Trastuzumab
Receptor tyrosine-protein kinase erbB-2 (ERBB2)
N10-beta-glucuronide SG3200
Mal-PEG8-Val-Ala-PABC
[9]
40H3-Tesirine
Anti-EGFR mAb 40H3
Epidermal growth factor receptor (EGFR)
SG3199
Mal-PEG8-Val-Ala-PABC
[15]
Anti-CD22- (LC:K149C)-SN36248
Pinatuzumab
B-cell receptor CD22 (CD22)
seco-CBI-dimer
Mal-PEG2
[16]
AT-03
Anti-CLDN6 antibody
CLDN6
TCS132 (AxcynDOT)
A cleavable linker
[17]
M276-SL-PBD
Anti-CD276 mAb m276-SL
CD276 antigen (CD276)
PBD dimer
Mc-Val-Ala
[18]
KTN0182A
Undisclosed
Mast/stem cell growth factor receptor Kit (KIT)
PBD dimer
Undisclosed
[19]
EV20/NMS-P945
EV20
Receptor tyrosine-protein kinase erbB-3 (ERBB3)
NMS-P528
Cathepsin-cleavable peptidic linker with self-immolating spacer
[20]
Trastuzumab-BCN-HydraSpace-Val-Cit-PABC-Gly-Calicheamicin
Trastuzumab
Receptor tyrosine-protein kinase erbB-2 (ERBB2)
Gly-calicheamicin
BCN-HydraSpace-Val-Cit-PABC
[21]
Trastuzumab SG-3259
Trastuzumab
Receptor tyrosine-protein kinase erbB-2 (ERBB2)
SG3312
Mc-Val-Ala
[22]
Trastuzumab-SG3400 high DAR
Trastuzumab
Receptor tyrosine-protein kinase erbB-2 (ERBB2)
SG3200
Mal-PEG8-Val-Ala-PABC
[9]
Promiximab-DUBA
Promiximab
Neural cell adhesion molecule 1 (NCAM1)
seco-DUBA
Mal-Val-Cit-PABA-Cyclization spacer
[23]
MUC16-Mc-Val-Cit-PABC-CBI dimer
Thio hu Anti-MUC16
Mucin-16 (MUC16)
seco-CBI-dimer
Mc-Val-Cit-PABC
[24]
Anti-CD22-SN36248
Anti-CD22 10F4 Thiomab (LC:K149C)
B-cell receptor CD22 (CD22)
seco-CBI-dimer
Mal-PEG2
[16]
T1LD7
Anti-IL1RL1 mAb
Interleukin-1 receptor-like 1 (IL1RL1)
N-acetyl-gamma-calicheamicin
Mal-Val-Cit-PABC-EDA
[25]
Recombinant humanized anti-EGFR mAb-DUO-5 conjugate
Undisclosed
Epidermal growth factor receptor (EGFR)
Duostatin 5
Undisclosed
[26]
HuB4-DGN462
Undisclosed
B-lymphocyte antigen CD19 (CD19)
DGN462
Sulfo-SPDB
[27]
B4-SPP-DC44
Anti-CD19 mAb B4
B-lymphocyte antigen CD19 (CD19)
DC44
N-succinimidyl 4-(2-pyridyldithio) pentanoate (SPP)
[28]
HuC242-SPP-DC4
Cantuzumab
Syndecan-1 (SDC1)
Phosphate prodrugs 40 (DC4)
N-succinimidyl 4-(2-pyridyldithio) pentanoate (SPP)
[28]
HuC242-SPDB-DC4
Cantuzumab
Syndecan-1 (SDC1)
Phosphate prodrugs 40 (DC4)
N-succinimidyl 4-(2-pyridyldithio) butanoate (SPDB)
[28]
HuC242-SMCC-DC4
Cantuzumab
Syndecan-1 (SDC1)
Phosphate prodrugs 40 (DC4)
Succinimidyl-4-(N-maleimidomethyl)cyclohexane-1-carboxylate (SMCC)
[28]
B4-SMCC-DC4
Anti-CD19 mAb B4
B-lymphocyte antigen CD19 (CD19)
Phosphate prodrugs 40 (DC4)
Succinimidyl-4-(N-maleimidomethyl)cyclohexane-1-carboxylate (SMCC)
[28]
B4-SPP-DC4
Anti-CD19 mAb B4
B-lymphocyte antigen CD19 (CD19)
Phosphate prodrugs 40 (DC4)
N-succinimidyl 4-(2-pyridyldithio) pentanoate (SPP)
[28]
B4-SPP-DC1
Anti-CD19 mAb B4
B-lymphocyte antigen CD19 (CD19)
DC1
N-succinimidyl 4-(2-pyridyldithio) pentanoate (SPP)
[28]
Anti-B4 monoclonal antibody-DC1 conjugate
Undisclosed
B-lymphocyte antigen CD19 (CD19)
DC1
Undisclosed
[29]
REGN-3124-PBD
REGN3124
Epidermal growth factor receptor variant III (EGFRvIII)
SG3199
Mal-PEG8-Val-Ala-PABC
[30]
CD25-ADC
Anti-CD25 mAb PC61
Interferon-stimulated gene 20 kDa protein (ISG20)
SG3199
Mal-PEG8-Val-Ala-PABC
[31]
HLL2-PBD
Epratuzumab
B-cell receptor CD22 (CD22)
SG3199
Mal-PEG8-Val-Ala-PABC
[32]
GFRA1 targeted antibody-drug conjugate
Anti-GFRA1 mAb
GDNF family receptor alpha-1 (GFRA1)
SG3199
Mal-PEG8-Val-Ala-PABC
[33]
MEDI-0641
5T4_0108
Trophoblast glycoprotein (TPBG)
5T4-PBD
Mal-PEG8-Val-Ala-PABC
[34]
Anti-CD30-LDM
Recombinant human CD30Fc fusion protein
Tumor necrosis factor receptor superfamily member 8 (TNFRSF8)
Lidamycin
Uncleavable linker
[35]
NV105
Undisclosed
CD276 antigen (CD276)
Temozolomide
Undisclosed
[36]
CD33-CPI dimer ADC
Anti-CD33 Anti-ody 11A1
Myeloid cell surface antigen CD33 (CD33)
Bicyclopentyl-seco-CBI-dimer
AcLys-Val-Cit-PABC-DMAE
[37]
HuN901-CC-1065
Lorvotuzumab
Neural cell adhesion molecule 1 (NCAM1)
Rachelmycin
Cleavable disulfide
[38]
Monoclonal antibody A5B7-cisplatin conjugate
Anti-CEACAM5 mAb A5B7
Pregnancy-specific beta-1-glycoprotein 2 (PSG2)
Cisplatin
Undisclosed
[39]
PYX-203
Undisclosed
Interleukin-3 receptor subunit alpha (IL3RA)
Cyclopropylpyrroloindole (CPI) DNA-damaging payload
Lysosomal cleavable linker
[40]
CD123-CPI ADC (Pfizer)
Undisclosed
Interleukin-3 receptor subunit alpha (IL3RA)
Cyclopropylpyrroloindoline (CPI) payload
Undisclosed
[41]
CLL1-ADC
Fully humanized Anti-CLL1 mAb
C-type lectin domain family 12 member A (CLEC12A)
D211
Mal-PEG8-Val-Cit-PABC
[42]
CyEt-Pan-Duo
Panitumumab
Epidermal growth factor receptor (EGFR)
DEAEA duocarmycin
Mal-PEG4-Triazol-Cyanine cage
[43]
Anti-PDGFRB cotinine scFv-C-scFv-duocarmycin
Bispecific Anti-PDGFRB + cotinine scFv-C-scFv fusion protein
Platelet-derived growth factor receptor beta (PDGFRB)
DEAEA duocarmycin
PEG3-Val-Cit-PABC
[44]
RC58-ADC-1
RC58
B-lymphocyte antigen CD19 (CD19)
Dumycin-7
Bis-bromine linker-PEG4-Asn-Ala-ethylenediamine
[45]
D2B-DCM
Anti-PSMA mAb D2B
Glutamate carboxypeptidase 2 (FOLH1)
Duocarmycin A
Mc-Val-Cit-PABC
[46]
B2M-duocarmycin ADC
LS-B2200
Beta-2-microglobulin (B2M)
Duocarmycin A
Bis-Tolylsulfonyl-Propanoyl-Benzamide-Glu-NH-PEG(24u)-OMe-Val-Cit-PAB
[47]
Anti-PDGFRB C-scFv Duocarmycin
Anti-mouse PDGFRB Anti-ody
Platelet-derived growth factor receptor beta (PDGFRB)
Duocarmycin A
Undisclosed
[44]
ENDOS/ADC
Anti-CD248 mAb hMP-E-8.3
Endosialin (CD248)
Duocarmycin derivative
Val-Cit
[48]
Trastuzumab-BCN-HydraSpace-Val-Cit-PABC-Duocarmycin
Trastuzumab
Receptor tyrosine-protein kinase erbB-2 (ERBB2)
Duocarmycin Sa
BCN-HydraSpace-Val-Cit-PABC
[21]
HYP7-DC
Humanized GPC3-specific Anti-ody YP7
Glypican-3 (GPC3)
Duocarmycin Sa
Mal-PEG4-Val-Cit-PABC-DMAE
[49]
PCM5B14-DCM
H5B14
Macrophage-stimulating protein receptor (MST1R)
Duocarmycin Sa
Mc-PEG4-Val-Cit-PABC-DMAE
[50]
Cotinine-duocarmycin
ERC6 bispecific Anti-ody (fuse Anti-cotinine scFv to cetuximab CH3 domain)
Epidermal growth factor receptor (EGFR)
Duocarmycin Sa
Mc-Val-Cit-PABC-DMAE
[44]
GPR56-ADC
Anti-GPR56 Anti-ody 10C7
Adhesion G-protein coupled receptor G1 (ADGRG1)
Duocarmycin Sa
Mal-Val-Cit-PABC-DMEA-PEG2
[51]
ZV-0508
ZV05
Trophoblast glycoprotein (TPBG)
Duostatin 5
C-Lock-ANN tri-peptide
[52]
Adalimumab fosimdesonide
Adalimumab
Tumor necrosis factor (TNF)
SGD-1882
Undisclosed
[53]
CIRCR201-dPBD
Anti-MET mAb cIRCR201
Hepatocyte growth factor receptor (MET)
Glucuronide-dPBD
Iso-PEG5-beta-glucuronide
[54]
LA22-MMC
Anti-EGFR mAb LA22
Epidermal growth factor receptor (EGFR)
Mitomycin C
N-succinimidyl 3-(2-pyridyldithio) propionate (SPDP)
[55]
Trastuzumab-BCN-HydraSpace-Val-Cit-PABC-Calicheamicin
Trastuzumab
Receptor tyrosine-protein kinase erbB-2 (ERBB2)
N-acetyl-gamma-calicheamicin
BCN-HydraSpace-Val-Cit-PABC
[21]
T1LD6
Anti-IL1RL1 mAb
Interleukin-1 receptor-like 1 (IL1RL1)
N-methyl-uncialamycin
Mal-Val-Cit-gucuronide-PEG8-PABC
[25]
T1LD5
Anti-IL1RL1 mAb
Interleukin-1 receptor-like 1 (IL1RL1)
N-methyl-uncialamycin
Mal-Val-Cit-glucuronide-PABC
[25]
T1LD4
Anti-IL1RL1 mAb
Interleukin-1 receptor-like 1 (IL1RL1)
N-methyl-uncialamycin
Mal-glucuronidase cleavable linker
[25]
T1LD3
Anti-IL1RL1 mAb
Interleukin-1 receptor-like 1 (IL1RL1)
N-methyl-uncialamycin
Mal-PEG8
[25]
T1LD2
Anti-IL1RL1 mAb
Interleukin-1 receptor-like 1 (IL1RL1)
N-methyl-uncialamycin
Mal-acetic acid
[25]
T1LD1
Anti-IL1RL1 mAb
Interleukin-1 receptor-like 1 (IL1RL1)
N-methyl-uncialamycin
Mal-Val-Cit-PABC
[25]
T2LD6
Anti-CD46 mAb
Membrane cofactor protein (CD46)
N-methyl-uncialamycin
Mal-Val-Cit-gucuronide-PEG8-PABC
[25]
T2LD5
Anti-CD46 mAb
Membrane cofactor protein (CD46)
N-methyl-uncialamycin
Mal-Val-Cit-glucuronide-PABC
[25]
T2LD4
Anti-CD46 mAb
Membrane cofactor protein (CD46)
N-methyl-uncialamycin
Mal-glucuronidase cleavable linker
[25]
T2LD3
Anti-CD46 mAb
Membrane cofactor protein (CD46)
N-methyl-uncialamycin
Mal-PEG8
[25]
T2LD2
Anti-CD46 mAb
Membrane cofactor protein (CD46)
N-methyl-uncialamycin
Mal-acetic acid
[25]
T2LD1
Anti-CD46 mAb
Membrane cofactor protein (CD46)
N-methyl-uncialamycin
Mal-Val-Cit-PABC
[25]
ACD22-LC-K149C-10
Anti-CD22-LC-K149C
B-cell receptor CD22 (CD22)
PA-seco-CBI-dimer
Mc-cBu-Cit
[56]
Anti-ICOS-PBD
Murine Anti-ICOS Anti-ody
Inducible T-cell costimulator (ICOS)
PBD dimer
Undisclosed
[57]
Masked ADC (Adagene/ADC Therapeutics)
Undisclosed
Undisclosed
PBD dimer
Undisclosed
[58]
Trastuzumab-BCN-HydraSpace-Val-Ala-PABC-PBD dimer
Trastuzumab
Receptor tyrosine-protein kinase erbB-2 (ERBB2)
PBD dimer 2
BCN-HydraSpace-Val-Ala-PABC
[21]
Trastuzumab-DNA mimic 4
Trastuzumab
Receptor tyrosine-protein kinase erbB-2 (ERBB2)
Q Pho-DNA mimics
Diphenyltio-Mal-Cap
[59]
ADCT-211
Anti-IL13RA2 mAb huCl47
Interleukin-13 receptor subunit alpha-2 (IL13RA2)
SG2000
Vali-Ala cleavable linker
[60]
ADCT-212
Undisclosed
Prostate-specific antigen (KLK3)
SG2000
Vali-Ala cleavable linker
[61]
Anti-IL13RA2 PBD ADC
Anti-IL13RA2 mAb 2E10
Interleukin-13 receptor subunit alpha-2 (IL13RA2)
SGD-1882
Mc-Val-Ala
[62]
Anti-FucGM1-45 ADC
Anti-FucGM1 mAb
Fucosylated monosialotetrahexosylganglioside (FucGM1)
Tetrahydroisoquinoline-based PBD dimer 17
Mc-Val-Cit-PABC
[63]
Anti-FucGM1-46 ADC
Anti-FucGM1 mAb
Fucosylated monosialotetrahexosylganglioside (FucGM1)
Tetrahydroisoquinoline-based PBD dimer 17
PEG2-Val-Cit-PABC
[63]
Anti-FucGM1-47 ADC
Anti-FucGM1 mAb
Fucosylated monosialotetrahexosylganglioside (FucGM1)
Tetrahydroisoquinoline-based PBD dimer 17
PEG4-Val-Cit-PABC
[63]
Anti-FucGM1-48 ADC
Anti-FucGM1 mAb
Fucosylated monosialotetrahexosylganglioside (FucGM1)
Tetrahydroisoquinoline-based PBD dimer 17
PEG8-Val-Cit-PABC
[63]
Anti-CD70-45 ADC
Anti-CD70 mAb
CD70 antigen (CD70)
Tetrahydroisoquinoline-based PBD dimer 17
Mc-Val-Cit-PABC
[63]
Anti-MSLN-45 ADC
Anti-MSLN mAb
Mesothelin (MSLN)
Tetrahydroisoquinoline-based PBD dimer 17
Mc-Val-Cit-PABC
[63]
Anti-MSLN-46 ADC
Anti-MSLN mAb
Mesothelin (MSLN)
Tetrahydroisoquinoline-based PBD dimer 17
PEG2-Val-Cit-PABC
[63]
Anti-MSLN-47 ADC
Anti-MSLN mAb
Mesothelin (MSLN)
Tetrahydroisoquinoline-based PBD dimer 17
PEG4-Val-Cit-PABC
[63]
Anti-MSLN-48 ADC
Anti-MSLN mAb
Mesothelin (MSLN)
Tetrahydroisoquinoline-based PBD dimer 17
PEG8-Val-Cit-PABC
[63]
Anti-MSLN-44 ADC
Anti-MSLN mAb
Mesothelin (MSLN)
Tetrahydroisoquinoline-based PBD dimer 14
Mal-PEG8-Val-Cit-PABC
[63]
IKS-01
Isumab01
Folate receptor alpha (FOLR1)
FGX2-62
Undisclosed
[64]
IPH43
Glycosylated Anti-MICA Anti-ody
MHC class I polypeptide-related sequence A (MICA)
PBD dimer
Undisclosed
[65]
SC16.3-DL2
SC16.3
Delta-like protein 3 (DLL3)
SG3312
Mc-Val-Ala
[66]
SC16.4-DL2
SC16.4
Delta-like protein 3 (DLL3)
SG3312
Mc-Val-Ala
[66]
SC16.5-DL2
SC16.5
Delta-like protein 3 (DLL3)
SG3312
Mc-Val-Ala
[66]
SC16.7-DL2
SC16.7
Delta-like protein 3 (DLL3)
SG3312
Mc-Val-Ala
[66]
SC16.8-DL2
SC16.8
Delta-like protein 3 (DLL3)
SG3312
Mc-Val-Ala
[66]
SC16.10-DL2
SC16.10
Delta-like protein 3 (DLL3)
SG3312
Mc-Val-Ala
[66]
SC16.11-DL2
SC16.11
Delta-like protein 3 (DLL3)
SG3312
Mc-Val-Ala
[66]
SC16.13-DL2
SC16.13
Delta-like protein 3 (DLL3)
SG3312
Mc-Val-Ala
[66]
SC16.15-DL2
SC16.15
Delta-like protein 3 (DLL3)
SG3312
Mc-Val-Ala
[66]
SC16.18-DL2
SC16.18
Delta-like protein 3 (DLL3)
SG3312
Mc-Val-Ala
[66]
SC16.19-DL2
SC16.19
Delta-like protein 3 (DLL3)
SG3312
Mc-Val-Ala
[66]
SC16.20-DL2
SC16.20
Delta-like protein 3 (DLL3)
SG3312
Mc-Val-Ala
[66]
SC16.21-DL2
SC16.21
Delta-like protein 3 (DLL3)
SG3312
Mc-Val-Ala
[66]
SC16.22-DL2
SC16.22
Delta-like protein 3 (DLL3)
SG3312
Mc-Val-Ala
[66]
SC16.23-DL2
SC16.23
Delta-like protein 3 (DLL3)
SG3312
Mc-Val-Ala
[66]
SC16.25-DL2
SC16.25
Delta-like protein 3 (DLL3)
SG3312
Mc-Val-Ala
[66]
SC16.26-DL2
SC16.26
Delta-like protein 3 (DLL3)
SG3312
Mc-Val-Ala
[66]
SC16.29-DL2
SC16.29
Delta-like protein 3 (DLL3)
SG3312
Mc-Val-Ala
[66]
SC16.30-DL2
SC16.30
Delta-like protein 3 (DLL3)
SG3312
Mc-Val-Ala
[66]
SC16.31-DL2
SC16.31
Delta-like protein 3 (DLL3)
SG3312
Mc-Val-Ala
[66]
SC16.34-DL2
SC16.34
Delta-like protein 3 (DLL3)
SG3312
Mc-Val-Ala
[66]
SC16.35-DL2
SC16.35
Delta-like protein 3 (DLL3)
SG3312
Mc-Val-Ala
[66]
SC16.36-DL2
SC16.36
Delta-like protein 3 (DLL3)
SG3312
Mc-Val-Ala
[66]
SC16.38-DL2
SC16.38
Delta-like protein 3 (DLL3)
SG3312
Mc-Val-Ala
[66]
SC16.41-DL2
SC16.41
Delta-like protein 3 (DLL3)
SG3312
Mc-Val-Ala
[66]
SC16.42-DL2
SC16.42
Delta-like protein 3 (DLL3)
SG3312
Mc-Val-Ala
[66]
SC16.45-DL2
SC16.45
Delta-like protein 3 (DLL3)
SG3312
Mc-Val-Ala
[66]
SC16.47-DL2
SC16.47
Delta-like protein 3 (DLL3)
SG3312
Mc-Val-Ala
[66]
SC16.49-DL2
SC16.49
Delta-like protein 3 (DLL3)
SG3312
Mc-Val-Ala
[66]
SC16.50-DL2
SC16.50
Delta-like protein 3 (DLL3)
SG3312
Mc-Val-Ala
[66]
SC16.52-DL2
SC16.52
Delta-like protein 3 (DLL3)
SG3312
Mc-Val-Ala
[66]
SC16.55-DL2
SC16.55
Delta-like protein 3 (DLL3)
SG3312
Mc-Val-Ala
[66]
SC16.56-DL2
SC16.56
Delta-like protein 3 (DLL3)
SG3312
Mc-Val-Ala
[66]
SC16.57-DL2
SC16.57
Delta-like protein 3 (DLL3)
SG3312
Mc-Val-Ala
[66]
SC16.58-DL2
SC16.58
Delta-like protein 3 (DLL3)
SG3312
Mc-Val-Ala
[66]
SC16.61-DL2
SC16.61
Delta-like protein 3 (DLL3)
SG3312
Mc-Val-Ala
[66]
SC16.62-DL2
SC16.62
Delta-like protein 3 (DLL3)
SG3312
Mc-Val-Ala
[66]
SC16.63-DL2
SC16.63
Delta-like protein 3 (DLL3)
SG3312
Mc-Val-Ala
[66]
SC16.65-DL2
SC16.65
Delta-like protein 3 (DLL3)
SG3312
Mc-Val-Ala
[66]
SC16.67-DL2
SC16.67
Delta-like protein 3 (DLL3)
SG3312
Mc-Val-Ala
[66]
SC16.68-DL2
SC16.68
Delta-like protein 3 (DLL3)
SG3312
Mc-Val-Ala
[66]
SC16.72-DL2
SC16.72
Delta-like protein 3 (DLL3)
SG3312
Mc-Val-Ala
[66]
SC16.73-DL2
SC16.73
Delta-like protein 3 (DLL3)
SG3312
Mc-Val-Ala
[66]
SC16.78-DL2
SC16.78
Delta-like protein 3 (DLL3)
SG3312
Mc-Val-Ala
[66]
SC16.79-DL2
SC16.79
Delta-like protein 3 (DLL3)
SG3312
Mc-Val-Ala
[66]
SC16.80-DL2
SC16.80
Delta-like protein 3 (DLL3)
SG3312
Mc-Val-Ala
[66]
SC16.81-DL2
SC16.81
Delta-like protein 3 (DLL3)
SG3312
Mc-Val-Ala
[66]
SC16.84-DL2
SC16.84
Delta-like protein 3 (DLL3)
SG3312
Mc-Val-Ala
[66]
SC16.88-DL2
SC16.88
Delta-like protein 3 (DLL3)
SG3312
Mc-Val-Ala
[66]
SC16.101-DL2
SC16.101
Delta-like protein 3 (DLL3)
SG3312
Mc-Val-Ala
[66]
SC16.103-DL2
SC16.103
Delta-like protein 3 (DLL3)
SG3312
Mc-Val-Ala
[66]
SC16.104-DL2
SC16.104
Delta-like protein 3 (DLL3)
SG3312
Mc-Val-Ala
[66]
SC16.105-DL2
SC16.105
Delta-like protein 3 (DLL3)
SG3312
Mc-Val-Ala
[66]
SC16.106-DL2
SC16.106
Delta-like protein 3 (DLL3)
SG3312
Mc-Val-Ala
[66]
SC16.107-DL2
SC16.107
Delta-like protein 3 (DLL3)
SG3312
Mc-Val-Ala
[66]
SC16.108-DL2
SC16.108
Delta-like protein 3 (DLL3)
SG3312
Mc-Val-Ala
[66]
SC16.109-DL2
SC16.109
Delta-like protein 3 (DLL3)
SG3312
Mc-Val-Ala
[66]
SC16.110-DL2
SC16.110
Delta-like protein 3 (DLL3)
SG3312
Mc-Val-Ala
[66]
SC16.111-DL2
SC16.111
Delta-like protein 3 (DLL3)
SG3312
Mc-Val-Ala
[66]
SC16.113-DL2
SC16.113
Delta-like protein 3 (DLL3)
SG3312
Mc-Val-Ala
[66]
SC16.114-DL2
SC16.114
Delta-like protein 3 (DLL3)
SG3312
Mc-Val-Ala
[66]
SC16.115-DL2
SC16.115
Delta-like protein 3 (DLL3)
SG3312
Mc-Val-Ala
[66]
SC16.116-DL2
SC16.116
Delta-like protein 3 (DLL3)
SG3312
Mc-Val-Ala
[66]
SC16.117-DL2
SC16.117
Delta-like protein 3 (DLL3)
SG3312
Mc-Val-Ala
[66]
SC16.118-DL2
SC16.118
Delta-like protein 3 (DLL3)
SG3312
Mc-Val-Ala
[66]
SC16.120-DL2
SC16.120
Delta-like protein 3 (DLL3)
SG3312
Mc-Val-Ala
[66]
SC16.121-DL2
SC16.121
Delta-like protein 3 (DLL3)
SG3312
Mc-Val-Ala
[66]
SC16.122-DL2
SC16.122
Delta-like protein 3 (DLL3)
SG3312
Mc-Val-Ala
[66]
SC16.123-DL2
SC16.123
Delta-like protein 3 (DLL3)
SG3312
Mc-Val-Ala
[66]
SC16.124-DL2
SC16.124
Delta-like protein 3 (DLL3)
SG3312
Mc-Val-Ala
[66]
SC16.125-DL2
SC16.125
Delta-like protein 3 (DLL3)
SG3312
Mc-Val-Ala
[66]
SC16.126-DL2
SC16.126
Delta-like protein 3 (DLL3)
SG3312
Mc-Val-Ala
[66]
SC16.129-DL2
SC16.129
Delta-like protein 3 (DLL3)
SG3312
Mc-Val-Ala
[66]
SC16.130-DL2
SC16.130
Delta-like protein 3 (DLL3)
SG3312
Mc-Val-Ala
[66]
SC16.131-DL2
SC16.131
Delta-like protein 3 (DLL3)
SG3312
Mc-Val-Ala
[66]
SC16.132-DL2
SC16.132
Delta-like protein 3 (DLL3)
SG3312
Mc-Val-Ala
[66]
SC16.133-DL2
SC16.133
Delta-like protein 3 (DLL3)
SG3312
Mc-Val-Ala
[66]
SC16.134-DL2
SC16.134
Delta-like protein 3 (DLL3)
SG3312
Mc-Val-Ala
[66]
SC16.135-DL2
SC16.135
Delta-like protein 3 (DLL3)
SG3312
Mc-Val-Ala
[66]
SC16.136-DL2
SC16.136
Delta-like protein 3 (DLL3)
SG3312
Mc-Val-Ala
[66]
SC16.137-DL2
SC16.137
Delta-like protein 3 (DLL3)
SG3312
Mc-Val-Ala
[66]
SC16.138-DL2
SC16.138
Delta-like protein 3 (DLL3)
SG3312
Mc-Val-Ala
[66]
SC16.139-DL2
SC16.139
Delta-like protein 3 (DLL3)
SG3312
Mc-Val-Ala
[66]
SC16.140-DL2
SC16.140
Delta-like protein 3 (DLL3)
SG3312
Mc-Val-Ala
[66]
SC16.141-DL2
SC16.141
Delta-like protein 3 (DLL3)
SG3312
Mc-Val-Ala
[66]
SC16.142-DL2
SC16.142
Delta-like protein 3 (DLL3)
SG3312
Mc-Val-Ala
[66]
SC16.143-DL2
SC16.143
Delta-like protein 3 (DLL3)
SG3312
Mc-Val-Ala
[66]
SC16.144-DL2
SC16.144
Delta-like protein 3 (DLL3)
SG3312
Mc-Val-Ala
[66]
SC16.147-DL2
SC16.147
Delta-like protein 3 (DLL3)
SG3312
Mc-Val-Ala
[66]
SC16.148-DL2
SC16.148
Delta-like protein 3 (DLL3)
SG3312
Mc-Val-Ala
[66]
SC16.149-DL2
SC16.149
Delta-like protein 3 (DLL3)
SG3312
Mc-Val-Ala
[66]
SC16.150-DL2
SC16.150
Delta-like protein 3 (DLL3)
SG3312
Mc-Val-Ala
[66]
SC16.3-DL3
SC16.3
Delta-like protein 3 (DLL3)
SG2000 derivative PBD 3
Mal-PEG8-Val-Ala
[66]
SC16.4-DL3
SC16.4
Delta-like protein 3 (DLL3)
SG2000 derivative PBD 3
Mal-PEG8-Val-Ala
[66]
SC16.5-DL3
SC16.5
Delta-like protein 3 (DLL3)
SG2000 derivative PBD 3
Mal-PEG8-Val-Ala
[66]
SC16.7-DL3
SC16.7
Delta-like protein 3 (DLL3)
SG2000 derivative PBD 3
Mal-PEG8-Val-Ala
[66]
SC16.8-DL3
SC16.8
Delta-like protein 3 (DLL3)
SG2000 derivative PBD 3
Mal-PEG8-Val-Ala
[66]
SC16.10-DL3
SC16.10
Delta-like protein 3 (DLL3)
SG2000 derivative PBD 3
Mal-PEG8-Val-Ala
[66]
SC16.11-DL3
SC16.11
Delta-like protein 3 (DLL3)
SG2000 derivative PBD 3
Mal-PEG8-Val-Ala
[66]
SC16.13-DL3
SC16.13
Delta-like protein 3 (DLL3)
SG2000 derivative PBD 3
Mal-PEG8-Val-Ala
[66]
SC16.15-DL3
SC16.15
Delta-like protein 3 (DLL3)
SG2000 derivative PBD 3
Mal-PEG8-Val-Ala
[66]
SC16.18-DL3
SC16.18
Delta-like protein 3 (DLL3)
SG2000 derivative PBD 3
Mal-PEG8-Val-Ala
[66]
SC16.19-DL3
SC16.19
Delta-like protein 3 (DLL3)
SG2000 derivative PBD 3
Mal-PEG8-Val-Ala
[66]
SC16.20-DL3
SC16.20
Delta-like protein 3 (DLL3)
SG2000 derivative PBD 3
Mal-PEG8-Val-Ala
[66]
SC16.21-DL3
SC16.21
Delta-like protein 3 (DLL3)
SG2000 derivative PBD 3
Mal-PEG8-Val-Ala
[66]
SC16.22-DL3
SC16.22
Delta-like protein 3 (DLL3)
SG2000 derivative PBD 3
Mal-PEG8-Val-Ala
[66]
SC16.23-DL3
SC16.23
Delta-like protein 3 (DLL3)
SG2000 derivative PBD 3
Mal-PEG8-Val-Ala
[66]
SC16.25-DL3
SC16.25
Delta-like protein 3 (DLL3)
SG2000 derivative PBD 3
Mal-PEG8-Val-Ala
[66]
SC16.26-DL3
SC16.26
Delta-like protein 3 (DLL3)
SG2000 derivative PBD 3
Mal-PEG8-Val-Ala
[66]
SC16.29-DL3
SC16.29
Delta-like protein 3 (DLL3)
SG2000 derivative PBD 3
Mal-PEG8-Val-Ala
[66]
SC16.30-DL3
SC16.30
Delta-like protein 3 (DLL3)
SG2000 derivative PBD 3
Mal-PEG8-Val-Ala
[66]
SC16.31-DL3
SC16.31
Delta-like protein 3 (DLL3)
SG2000 derivative PBD 3
Mal-PEG8-Val-Ala
[66]
SC16.34-DL3
SC16.34
Delta-like protein 3 (DLL3)
SG2000 derivative PBD 3
Mal-PEG8-Val-Ala
[66]
SC16.35-DL3
SC16.35
Delta-like protein 3 (DLL3)
SG2000 derivative PBD 3
Mal-PEG8-Val-Ala
[66]
SC16.36-DL3
SC16.36
Delta-like protein 3 (DLL3)
SG2000 derivative PBD 3
Mal-PEG8-Val-Ala
[66]
SC16.38-DL3
SC16.38
Delta-like protein 3 (DLL3)
SG2000 derivative PBD 3
Mal-PEG8-Val-Ala
[66]
SC16.41-DL3
SC16.41
Delta-like protein 3 (DLL3)
SG2000 derivative PBD 3
Mal-PEG8-Val-Ala
[66]
SC16.42-DL3
SC16.42
Delta-like protein 3 (DLL3)
SG2000 derivative PBD 3
Mal-PEG8-Val-Ala
[66]
SC16.45-DL3
SC16.45
Delta-like protein 3 (DLL3)
SG2000 derivative PBD 3
Mal-PEG8-Val-Ala
[66]
SC16.47-DL3
SC16.47
Delta-like protein 3 (DLL3)
SG2000 derivative PBD 3
Mal-PEG8-Val-Ala
[66]
SC16.49-DL3
SC16.49
Delta-like protein 3 (DLL3)
SG2000 derivative PBD 3
Mal-PEG8-Val-Ala
[66]
SC16.50-DL3
SC16.50
Delta-like protein 3 (DLL3)
SG2000 derivative PBD 3
Mal-PEG8-Val-Ala
[66]
SC16.52-DL3
SC16.52
Delta-like protein 3 (DLL3)
SG2000 derivative PBD 3
Mal-PEG8-Val-Ala
[66]
SC16.55-DL3
SC16.55
Delta-like protein 3 (DLL3)
SG2000 derivative PBD 3
Mal-PEG8-Val-Ala
[66]
SC16.56-DL3
SC16.56
Delta-like protein 3 (DLL3)
SG2000 derivative PBD 3
Mal-PEG8-Val-Ala
[66]
SC16.57-DL3
SC16.57
Delta-like protein 3 (DLL3)
SG2000 derivative PBD 3
Mal-PEG8-Val-Ala
[66]
SC16.58-DL3
SC16.58
Delta-like protein 3 (DLL3)
SG2000 derivative PBD 3
Mal-PEG8-Val-Ala
[66]
SC16.61-DL3
SC16.61
Delta-like protein 3 (DLL3)
SG2000 derivative PBD 3
Mal-PEG8-Val-Ala
[66]
SC16.62-DL3
SC16.62
Delta-like protein 3 (DLL3)
SG2000 derivative PBD 3
Mal-PEG8-Val-Ala
[66]
SC16.63-DL3
SC16.63
Delta-like protein 3 (DLL3)
SG2000 derivative PBD 3
Mal-PEG8-Val-Ala
[66]
SC16.65-DL3
SC16.65
Delta-like protein 3 (DLL3)
SG2000 derivative PBD 3
Mal-PEG8-Val-Ala
[66]
SC16.67-DL3
SC16.67
Delta-like protein 3 (DLL3)
SG2000 derivative PBD 3
Mal-PEG8-Val-Ala
[66]
SC16.68-DL3
SC16.68
Delta-like protein 3 (DLL3)
SG2000 derivative PBD 3
Mal-PEG8-Val-Ala
[66]
SC16.72-DL3
SC16.72
Delta-like protein 3 (DLL3)
SG2000 derivative PBD 3
Mal-PEG8-Val-Ala
[66]
SC16.73-DL3
SC16.73
Delta-like protein 3 (DLL3)
SG2000 derivative PBD 3
Mal-PEG8-Val-Ala
[66]
SC16.78-DL3
SC16.78
Delta-like protein 3 (DLL3)
SG2000 derivative PBD 3
Mal-PEG8-Val-Ala
[66]
SC16.79-DL3
SC16.79
Delta-like protein 3 (DLL3)
SG2000 derivative PBD 3
Mal-PEG8-Val-Ala
[66]
SC16.80-DL3
SC16.80
Delta-like protein 3 (DLL3)
SG2000 derivative PBD 3
Mal-PEG8-Val-Ala
[66]
SC16.81-DL3
SC16.81
Delta-like protein 3 (DLL3)
SG2000 derivative PBD 3
Mal-PEG8-Val-Ala
[66]
SC16.84-DL3
SC16.84
Delta-like protein 3 (DLL3)
SG2000 derivative PBD 3
Mal-PEG8-Val-Ala
[66]
SC16.88-DL3
SC16.88
Delta-like protein 3 (DLL3)
SG2000 derivative PBD 3
Mal-PEG8-Val-Ala
[66]
SC16.101-DL3
SC16.101
Delta-like protein 3 (DLL3)
SG2000 derivative PBD 3
Mal-PEG8-Val-Ala
[66]
SC16.103-DL3
SC16.103
Delta-like protein 3 (DLL3)
SG2000 derivative PBD 3
Mal-PEG8-Val-Ala
[66]
SC16.104-DL3
SC16.104
Delta-like protein 3 (DLL3)
SG2000 derivative PBD 3
Mal-PEG8-Val-Ala
[66]
SC16.105-DL3
SC16.105
Delta-like protein 3 (DLL3)
SG2000 derivative PBD 3
Mal-PEG8-Val-Ala
[66]
SC16.106-DL3
SC16.106
Delta-like protein 3 (DLL3)
SG2000 derivative PBD 3
Mal-PEG8-Val-Ala
[66]
SC16.107-DL3
SC16.107
Delta-like protein 3 (DLL3)
SG2000 derivative PBD 3
Mal-PEG8-Val-Ala
[66]
SC16.108-DL3
SC16.108
Delta-like protein 3 (DLL3)
SG2000 derivative PBD 3
Mal-PEG8-Val-Ala
[66]
SC16.109-DL3
SC16.109
Delta-like protein 3 (DLL3)
SG2000 derivative PBD 3
Mal-PEG8-Val-Ala
[66]
SC16.110-DL3
SC16.110
Delta-like protein 3 (DLL3)
SG2000 derivative PBD 3
Mal-PEG8-Val-Ala
[66]
SC16.111-DL3
SC16.111
Delta-like protein 3 (DLL3)
SG2000 derivative PBD 3
Mal-PEG8-Val-Ala
[66]
SC16.113-DL3
SC16.113
Delta-like protein 3 (DLL3)
SG2000 derivative PBD 3
Mal-PEG8-Val-Ala
[66]
SC16.114-DL3
SC16.114
Delta-like protein 3 (DLL3)
SG2000 derivative PBD 3
Mal-PEG8-Val-Ala
[66]
SC16.115-DL3
SC16.115
Delta-like protein 3 (DLL3)
SG2000 derivative PBD 3
Mal-PEG8-Val-Ala
[66]
SC16.116-DL3
SC16.116
Delta-like protein 3 (DLL3)
SG2000 derivative PBD 3
Mal-PEG8-Val-Ala
[66]
SC16.117-DL3
SC16.117
Delta-like protein 3 (DLL3)
SG2000 derivative PBD 3
Mal-PEG8-Val-Ala
[66]
SC16.118-DL3
SC16.118
Delta-like protein 3 (DLL3)
SG2000 derivative PBD 3
Mal-PEG8-Val-Ala
[66]
SC16.120-DL3
SC16.120
Delta-like protein 3 (DLL3)
SG2000 derivative PBD 3
Mal-PEG8-Val-Ala
[66]
SC16.121-DL3
SC16.121
Delta-like protein 3 (DLL3)
SG2000 derivative PBD 3
Mal-PEG8-Val-Ala
[66]
SC16.122-DL3
SC16.122
Delta-like protein 3 (DLL3)
SG2000 derivative PBD 3
Mal-PEG8-Val-Ala
[66]
SC16.123-DL3
SC16.123
Delta-like protein 3 (DLL3)
SG2000 derivative PBD 3
Mal-PEG8-Val-Ala
[66]
SC16.124-DL3
SC16.124
Delta-like protein 3 (DLL3)
SG2000 derivative PBD 3
Mal-PEG8-Val-Ala
[66]
SC16.125-DL3
SC16.125
Delta-like protein 3 (DLL3)
SG2000 derivative PBD 3
Mal-PEG8-Val-Ala
[66]
SC16.126-DL3
SC16.126
Delta-like protein 3 (DLL3)
SG2000 derivative PBD 3
Mal-PEG8-Val-Ala
[66]
SC16.129-DL3
SC16.129
Delta-like protein 3 (DLL3)
SG2000 derivative PBD 3
Mal-PEG8-Val-Ala
[66]
SC16.130-DL3
SC16.130
Delta-like protein 3 (DLL3)
SG2000 derivative PBD 3
Mal-PEG8-Val-Ala
[66]
SC16.131-DL3
SC16.131
Delta-like protein 3 (DLL3)
SG2000 derivative PBD 3
Mal-PEG8-Val-Ala
[66]
SC16.132-DL3
SC16.132
Delta-like protein 3 (DLL3)
SG2000 derivative PBD 3
Mal-PEG8-Val-Ala
[66]
SC16.133-DL3
SC16.133
Delta-like protein 3 (DLL3)
SG2000 derivative PBD 3
Mal-PEG8-Val-Ala
[66]
SC16.134-DL3
SC16.134
Delta-like protein 3 (DLL3)
SG2000 derivative PBD 3
Mal-PEG8-Val-Ala
[66]
SC16.135-DL3
SC16.135
Delta-like protein 3 (DLL3)
SG2000 derivative PBD 3
Mal-PEG8-Val-Ala
[66]
SC16.136-DL3
SC16.136
Delta-like protein 3 (DLL3)
SG2000 derivative PBD 3
Mal-PEG8-Val-Ala
[66]
SC16.137-DL3
SC16.137
Delta-like protein 3 (DLL3)
SG2000 derivative PBD 3
Mal-PEG8-Val-Ala
[66]
SC16.138-DL3
SC16.138
Delta-like protein 3 (DLL3)
SG2000 derivative PBD 3
Mal-PEG8-Val-Ala
[66]
SC16.139-DL3
SC16.139
Delta-like protein 3 (DLL3)
SG2000 derivative PBD 3
Mal-PEG8-Val-Ala
[66]
SC16.140-DL3
SC16.140
Delta-like protein 3 (DLL3)
SG2000 derivative PBD 3
Mal-PEG8-Val-Ala
[66]
SC16.141-DL3
SC16.141
Delta-like protein 3 (DLL3)
SG2000 derivative PBD 3
Mal-PEG8-Val-Ala
[66]
SC16.142-DL3
SC16.142
Delta-like protein 3 (DLL3)
SG2000 derivative PBD 3
Mal-PEG8-Val-Ala
[66]
SC16.143-DL3
SC16.143
Delta-like protein 3 (DLL3)
SG2000 derivative PBD 3
Mal-PEG8-Val-Ala
[66]
SC16.144-DL3
SC16.144
Delta-like protein 3 (DLL3)
SG2000 derivative PBD 3
Mal-PEG8-Val-Ala
[66]
SC16.147-DL3
SC16.147
Delta-like protein 3 (DLL3)
SG2000 derivative PBD 3
Mal-PEG8-Val-Ala
[66]
SC16.148-DL3
SC16.148
Delta-like protein 3 (DLL3)
SG2000 derivative PBD 3
Mal-PEG8-Val-Ala
[66]
SC16.149-DL3
SC16.149
Delta-like protein 3 (DLL3)
SG2000 derivative PBD 3
Mal-PEG8-Val-Ala
[66]
SC16.150-DL3
SC16.150
Delta-like protein 3 (DLL3)
SG2000 derivative PBD 3
Mal-PEG8-Val-Ala
[66]
SC16.3-DL4
SC16.3
Delta-like protein 3 (DLL3)
SG2219
Iodoacetamide-PEG4-Val-Ala-PABC
[66]
SC16.4-DL4
SC16.4
Delta-like protein 3 (DLL3)
SG2219
Iodoacetamide-PEG4-Val-Ala-PABC
[66]
SC16.5-DL4
SC16.5
Delta-like protein 3 (DLL3)
SG2219
Iodoacetamide-PEG4-Val-Ala-PABC
[66]
SC16.7-DL4
SC16.7
Delta-like protein 3 (DLL3)
SG2219
Iodoacetamide-PEG4-Val-Ala-PABC
[66]
SC16.8-DL4
SC16.8
Delta-like protein 3 (DLL3)
SG2219
Iodoacetamide-PEG4-Val-Ala-PABC
[66]
SC16.10-DL4
SC16.10
Delta-like protein 3 (DLL3)
SG2219
Iodoacetamide-PEG4-Val-Ala-PABC
[66]
SC16.11-DL4
SC16.11
Delta-like protein 3 (DLL3)
SG2219
Iodoacetamide-PEG4-Val-Ala-PABC
[66]
SC16.13-DL4
SC16.13
Delta-like protein 3 (DLL3)
SG2219
Iodoacetamide-PEG4-Val-Ala-PABC
[66]
SC16.15-DL4
SC16.15
Delta-like protein 3 (DLL3)
SG2219
Iodoacetamide-PEG4-Val-Ala-PABC
[66]
SC16.18-DL4
SC16.18
Delta-like protein 3 (DLL3)
SG2219
Iodoacetamide-PEG4-Val-Ala-PABC
[66]
SC16.19-DL4
SC16.19
Delta-like protein 3 (DLL3)
SG2219
Iodoacetamide-PEG4-Val-Ala-PABC
[66]
SC16.20-DL4
SC16.20
Delta-like protein 3 (DLL3)
SG2219
Iodoacetamide-PEG4-Val-Ala-PABC
[66]
SC16.21-DL4
SC16.21
Delta-like protein 3 (DLL3)
SG2219
Iodoacetamide-PEG4-Val-Ala-PABC
[66]
SC16.22-DL4
SC16.22
Delta-like protein 3 (DLL3)
SG2219
Iodoacetamide-PEG4-Val-Ala-PABC
[66]
SC16.23-DL4
SC16.23
Delta-like protein 3 (DLL3)
SG2219
Iodoacetamide-PEG4-Val-Ala-PABC
[66]
SC16.25-DL4
SC16.25
Delta-like protein 3 (DLL3)
SG2219
Iodoacetamide-PEG4-Val-Ala-PABC
[66]
SC16.26-DL4
SC16.26
Delta-like protein 3 (DLL3)
SG2219
Iodoacetamide-PEG4-Val-Ala-PABC
[66]
SC16.29-DL4
SC16.29
Delta-like protein 3 (DLL3)
SG2219
Iodoacetamide-PEG4-Val-Ala-PABC
[66]
SC16.30-DL4
SC16.30
Delta-like protein 3 (DLL3)
SG2219
Iodoacetamide-PEG4-Val-Ala-PABC
[66]
SC16.31-DL4
SC16.31
Delta-like protein 3 (DLL3)
SG2219
Iodoacetamide-PEG4-Val-Ala-PABC
[66]
SC16.34-DL4
SC16.34
Delta-like protein 3 (DLL3)
SG2219
Iodoacetamide-PEG4-Val-Ala-PABC
[66]
SC16.35-DL4
SC16.35
Delta-like protein 3 (DLL3)
SG2219
Iodoacetamide-PEG4-Val-Ala-PABC
[66]
SC16.36-DL4
SC16.36
Delta-like protein 3 (DLL3)
SG2219
Iodoacetamide-PEG4-Val-Ala-PABC
[66]
SC16.38-DL4
SC16.38
Delta-like protein 3 (DLL3)
SG2219
Iodoacetamide-PEG4-Val-Ala-PABC
[66]
SC16.41-DL4
SC16.41
Delta-like protein 3 (DLL3)
SG2219
Iodoacetamide-PEG4-Val-Ala-PABC
[66]
SC16.42-DL4
SC16.42
Delta-like protein 3 (DLL3)
SG2219
Iodoacetamide-PEG4-Val-Ala-PABC
[66]
SC16.45-DL4
SC16.45
Delta-like protein 3 (DLL3)
SG2219
Iodoacetamide-PEG4-Val-Ala-PABC
[66]
SC16.47-DL4
SC16.47
Delta-like protein 3 (DLL3)
SG2219
Iodoacetamide-PEG4-Val-Ala-PABC
[66]
SC16.49-DL4
SC16.49
Delta-like protein 3 (DLL3)
SG2219
Iodoacetamide-PEG4-Val-Ala-PABC
[66]
SC16.50-DL4
SC16.50
Delta-like protein 3 (DLL3)
SG2219
Iodoacetamide-PEG4-Val-Ala-PABC
[66]
SC16.52-DL4
SC16.52
Delta-like protein 3 (DLL3)
SG2219
Iodoacetamide-PEG4-Val-Ala-PABC
[66]
SC16.55-DL4
SC16.55
Delta-like protein 3 (DLL3)
SG2219
Iodoacetamide-PEG4-Val-Ala-PABC
[66]
SC16.56-DL4
SC16.56
Delta-like protein 3 (DLL3)
SG2219
Iodoacetamide-PEG4-Val-Ala-PABC
[66]
SC16.57-DL4
SC16.57
Delta-like protein 3 (DLL3)
SG2219
Iodoacetamide-PEG4-Val-Ala-PABC
[66]
SC16.58-DL4
SC16.58
Delta-like protein 3 (DLL3)
SG2219
Iodoacetamide-PEG4-Val-Ala-PABC
[66]
SC16.61-DL4
SC16.61
Delta-like protein 3 (DLL3)
SG2219
Iodoacetamide-PEG4-Val-Ala-PABC
[66]
SC16.62-DL4
SC16.62
Delta-like protein 3 (DLL3)
SG2219
Iodoacetamide-PEG4-Val-Ala-PABC
[66]
SC16.63-DL4
SC16.63
Delta-like protein 3 (DLL3)
SG2219
Iodoacetamide-PEG4-Val-Ala-PABC
[66]
SC16.65-DL4
SC16.65
Delta-like protein 3 (DLL3)
SG2219
Iodoacetamide-PEG4-Val-Ala-PABC
[66]
SC16.67-DL4
SC16.67
Delta-like protein 3 (DLL3)
SG2219
Iodoacetamide-PEG4-Val-Ala-PABC
[66]
SC16.68-DL4
SC16.68
Delta-like protein 3 (DLL3)
SG2219
Iodoacetamide-PEG4-Val-Ala-PABC
[66]
SC16.72-DL4
SC16.72
Delta-like protein 3 (DLL3)
SG2219
Iodoacetamide-PEG4-Val-Ala-PABC
[66]
SC16.73-DL4
SC16.73
Delta-like protein 3 (DLL3)
SG2219
Iodoacetamide-PEG4-Val-Ala-PABC
[66]
SC16.78-DL4
SC16.78
Delta-like protein 3 (DLL3)
SG2219
Iodoacetamide-PEG4-Val-Ala-PABC
[66]
SC16.79-DL4
SC16.79
Delta-like protein 3 (DLL3)
SG2219
Iodoacetamide-PEG4-Val-Ala-PABC
[66]
SC16.80-DL4
SC16.80
Delta-like protein 3 (DLL3)
SG2219
Iodoacetamide-PEG4-Val-Ala-PABC
[66]
SC16.81-DL4
SC16.81
Delta-like protein 3 (DLL3)
SG2219
Iodoacetamide-PEG4-Val-Ala-PABC
[66]
SC16.84-DL4
SC16.84
Delta-like protein 3 (DLL3)
SG2219
Iodoacetamide-PEG4-Val-Ala-PABC
[66]
SC16.88-DL4
SC16.88
Delta-like protein 3 (DLL3)
SG2219
Iodoacetamide-PEG4-Val-Ala-PABC
[66]
SC16.101-DL4
SC16.101
Delta-like protein 3 (DLL3)
SG2219
Iodoacetamide-PEG4-Val-Ala-PABC
[66]
SC16.103-DL4
SC16.103
Delta-like protein 3 (DLL3)
SG2219
Iodoacetamide-PEG4-Val-Ala-PABC
[66]
SC16.104-DL4
SC16.104
Delta-like protein 3 (DLL3)
SG2219
Iodoacetamide-PEG4-Val-Ala-PABC
[66]
SC16.105-DL4
SC16.105
Delta-like protein 3 (DLL3)
SG2219
Iodoacetamide-PEG4-Val-Ala-PABC
[66]
SC16.106-DL4
SC16.106
Delta-like protein 3 (DLL3)
SG2219
Iodoacetamide-PEG4-Val-Ala-PABC
[66]
SC16.107-DL4
SC16.107
Delta-like protein 3 (DLL3)
SG2219
Iodoacetamide-PEG4-Val-Ala-PABC
[66]
SC16.108-DL4
SC16.108
Delta-like protein 3 (DLL3)
SG2219
Iodoacetamide-PEG4-Val-Ala-PABC
[66]
SC16.109-DL4
SC16.109
Delta-like protein 3 (DLL3)
SG2219
Iodoacetamide-PEG4-Val-Ala-PABC
[66]
SC16.110-DL4
SC16.110
Delta-like protein 3 (DLL3)
SG2219
Iodoacetamide-PEG4-Val-Ala-PABC
[66]
SC16.111-DL4
SC16.111
Delta-like protein 3 (DLL3)
SG2219
Iodoacetamide-PEG4-Val-Ala-PABC
[66]
SC16.113-DL4
SC16.113
Delta-like protein 3 (DLL3)
SG2219
Iodoacetamide-PEG4-Val-Ala-PABC
[66]
SC16.114-DL4
SC16.114
Delta-like protein 3 (DLL3)
SG2219
Iodoacetamide-PEG4-Val-Ala-PABC
[66]
SC16.115-DL4
SC16.115
Delta-like protein 3 (DLL3)
SG2219
Iodoacetamide-PEG4-Val-Ala-PABC
[66]
SC16.116-DL4
SC16.116
Delta-like protein 3 (DLL3)
SG2219
Iodoacetamide-PEG4-Val-Ala-PABC
[66]
SC16.117-DL4
SC16.117
Delta-like protein 3 (DLL3)
SG2219
Iodoacetamide-PEG4-Val-Ala-PABC
[66]
SC16.118-DL4
SC16.118
Delta-like protein 3 (DLL3)
SG2219
Iodoacetamide-PEG4-Val-Ala-PABC
[66]
SC16.120-DL4
SC16.120
Delta-like protein 3 (DLL3)
SG2219
Iodoacetamide-PEG4-Val-Ala-PABC
[66]
SC16.121-DL4
SC16.121
Delta-like protein 3 (DLL3)
SG2219
Iodoacetamide-PEG4-Val-Ala-PABC
[66]
SC16.122-DL4
SC16.122
Delta-like protein 3 (DLL3)
SG2219
Iodoacetamide-PEG4-Val-Ala-PABC
[66]
SC16.123-DL4
SC16.123
Delta-like protein 3 (DLL3)
SG2219
Iodoacetamide-PEG4-Val-Ala-PABC
[66]
SC16.124-DL4
SC16.124
Delta-like protein 3 (DLL3)
SG2219
Iodoacetamide-PEG4-Val-Ala-PABC
[66]
SC16.125-DL4
SC16.125
Delta-like protein 3 (DLL3)
SG2219
Iodoacetamide-PEG4-Val-Ala-PABC
[66]
SC16.126-DL4
SC16.126
Delta-like protein 3 (DLL3)
SG2219
Iodoacetamide-PEG4-Val-Ala-PABC
[66]
SC16.129-DL4
SC16.129
Delta-like protein 3 (DLL3)
SG2219
Iodoacetamide-PEG4-Val-Ala-PABC
[66]
SC16.130-DL4
SC16.130
Delta-like protein 3 (DLL3)
SG2219
Iodoacetamide-PEG4-Val-Ala-PABC
[66]
SC16.131-DL4
SC16.131
Delta-like protein 3 (DLL3)
SG2219
Iodoacetamide-PEG4-Val-Ala-PABC
[66]
SC16.132-DL4
SC16.132
Delta-like protein 3 (DLL3)
SG2219
Iodoacetamide-PEG4-Val-Ala-PABC
[66]
SC16.133-DL4
SC16.133
Delta-like protein 3 (DLL3)
SG2219
Iodoacetamide-PEG4-Val-Ala-PABC
[66]
SC16.134-DL4
SC16.134
Delta-like protein 3 (DLL3)
SG2219
Iodoacetamide-PEG4-Val-Ala-PABC
[66]
SC16.135-DL4
SC16.135
Delta-like protein 3 (DLL3)
SG2219
Iodoacetamide-PEG4-Val-Ala-PABC
[66]
SC16.136-DL4
SC16.136
Delta-like protein 3 (DLL3)
SG2219
Iodoacetamide-PEG4-Val-Ala-PABC
[66]
SC16.137-DL4
SC16.137
Delta-like protein 3 (DLL3)
SG2219
Iodoacetamide-PEG4-Val-Ala-PABC
[66]
SC16.138-DL4
SC16.138
Delta-like protein 3 (DLL3)
SG2219
Iodoacetamide-PEG4-Val-Ala-PABC
[66]
SC16.139-DL4
SC16.139
Delta-like protein 3 (DLL3)
SG2219
Iodoacetamide-PEG4-Val-Ala-PABC
[66]
SC16.140-DL4
SC16.140
Delta-like protein 3 (DLL3)
SG2219
Iodoacetamide-PEG4-Val-Ala-PABC
[66]
SC16.141-DL4
SC16.141
Delta-like protein 3 (DLL3)
SG2219
Iodoacetamide-PEG4-Val-Ala-PABC
[66]
SC16.142-DL4
SC16.142
Delta-like protein 3 (DLL3)
SG2219
Iodoacetamide-PEG4-Val-Ala-PABC
[66]
SC16.143-DL4
SC16.143
Delta-like protein 3 (DLL3)
SG2219
Iodoacetamide-PEG4-Val-Ala-PABC
[66]
SC16.144-DL4
SC16.144
Delta-like protein 3 (DLL3)
SG2219
Iodoacetamide-PEG4-Val-Ala-PABC
[66]
SC16.147-DL4
SC16.147
Delta-like protein 3 (DLL3)
SG2219
Iodoacetamide-PEG4-Val-Ala-PABC
[66]
SC16.148-DL4
SC16.148
Delta-like protein 3 (DLL3)
SG2219
Iodoacetamide-PEG4-Val-Ala-PABC
[66]
SC16.149-DL4
SC16.149
Delta-like protein 3 (DLL3)
SG2219
Iodoacetamide-PEG4-Val-Ala-PABC
[66]
SC16.150-DL4
SC16.150
Delta-like protein 3 (DLL3)
SG2219
Iodoacetamide-PEG4-Val-Ala-PABC
[66]
SC16.3-DL5
SC16.3
Delta-like protein 3 (DLL3)
SG3199
Mc-PEG8-Val-Ala-PABC
[66]
SC16.4-DL5
SC16.4
Delta-like protein 3 (DLL3)
SG3199
Mc-PEG8-Val-Ala-PABC
[66]
SC16.5-DL5
SC16.5
Delta-like protein 3 (DLL3)
SG3199
Mc-PEG8-Val-Ala-PABC
[66]
SC16.7-DL5
SC16.7
Delta-like protein 3 (DLL3)
SG3199
Mc-PEG8-Val-Ala-PABC
[66]
SC16.8-DL5
SC16.8
Delta-like protein 3 (DLL3)
SG3199
Mc-PEG8-Val-Ala-PABC
[66]
SC16.10-DL5
SC16.10
Delta-like protein 3 (DLL3)
SG3199
Mc-PEG8-Val-Ala-PABC
[66]
SC16.11-DL5
SC16.11
Delta-like protein 3 (DLL3)
SG3199
Mc-PEG8-Val-Ala-PABC
[66]
SC16.13-DL5
SC16.13
Delta-like protein 3 (DLL3)
SG3199
Mc-PEG8-Val-Ala-PABC
[66]
SC16.15-DL5
SC16.15
Delta-like protein 3 (DLL3)
SG3199
Mc-PEG8-Val-Ala-PABC
[66]
SC16.18-DL5
SC16.18
Delta-like protein 3 (DLL3)
SG3199
Mc-PEG8-Val-Ala-PABC
[66]
SC16.19-DL5
SC16.19
Delta-like protein 3 (DLL3)
SG3199
Mc-PEG8-Val-Ala-PABC
[66]
SC16.20-DL5
SC16.20
Delta-like protein 3 (DLL3)
SG3199
Mc-PEG8-Val-Ala-PABC
[66]
SC16.21-DL5
SC16.21
Delta-like protein 3 (DLL3)
SG3199
Mc-PEG8-Val-Ala-PABC
[66]
SC16.22-DL5
SC16.22
Delta-like protein 3 (DLL3)
SG3199
Mc-PEG8-Val-Ala-PABC
[66]
SC16.23-DL5
SC16.23
Delta-like protein 3 (DLL3)
SG3199
Mc-PEG8-Val-Ala-PABC
[66]
SC16.25-DL5
SC16.25
Delta-like protein 3 (DLL3)
SG3199
Mc-PEG8-Val-Ala-PABC
[66]
SC16.26-DL5
SC16.26
Delta-like protein 3 (DLL3)
SG3199
Mc-PEG8-Val-Ala-PABC
[66]
SC16.29-DL5
SC16.29
Delta-like protein 3 (DLL3)
SG3199
Mc-PEG8-Val-Ala-PABC
[66]
SC16.30-DL5
SC16.30
Delta-like protein 3 (DLL3)
SG3199
Mc-PEG8-Val-Ala-PABC
[66]
SC16.31-DL5
SC16.31
Delta-like protein 3 (DLL3)
SG3199
Mc-PEG8-Val-Ala-PABC
[66]
SC16.34-DL5
SC16.34
Delta-like protein 3 (DLL3)
SG3199
Mc-PEG8-Val-Ala-PABC
[66]
SC16.35-DL5
SC16.35
Delta-like protein 3 (DLL3)
SG3199
Mc-PEG8-Val-Ala-PABC
[66]
SC16.36-DL5
SC16.36
Delta-like protein 3 (DLL3)
SG3199
Mc-PEG8-Val-Ala-PABC
[66]
SC16.38-DL5
SC16.38
Delta-like protein 3 (DLL3)
SG3199
Mc-PEG8-Val-Ala-PABC
[66]
SC16.41-DL5
SC16.41
Delta-like protein 3 (DLL3)
SG3199
Mc-PEG8-Val-Ala-PABC
[66]
SC16.42-DL5
SC16.42
Delta-like protein 3 (DLL3)
SG3199
Mc-PEG8-Val-Ala-PABC
[66]
SC16.45-DL5
SC16.45
Delta-like protein 3 (DLL3)
SG3199
Mc-PEG8-Val-Ala-PABC
[66]
SC16.47-DL5
SC16.47
Delta-like protein 3 (DLL3)
SG3199
Mc-PEG8-Val-Ala-PABC
[66]
SC16.49-DL5
SC16.49
Delta-like protein 3 (DLL3)
SG3199
Mc-PEG8-Val-Ala-PABC
[66]
SC16.50-DL5
SC16.50
Delta-like protein 3 (DLL3)
SG3199
Mc-PEG8-Val-Ala-PABC
[66]
SC16.52-DL5
SC16.52
Delta-like protein 3 (DLL3)
SG3199
Mc-PEG8-Val-Ala-PABC
[66]
SC16.55-DL5
SC16.55
Delta-like protein 3 (DLL3)
SG3199
Mc-PEG8-Val-Ala-PABC
[66]
SC16.56-DL5
SC16.56
Delta-like protein 3 (DLL3)
SG3199
Mc-PEG8-Val-Ala-PABC
[66]
SC16.57-DL5
SC16.57
Delta-like protein 3 (DLL3)
SG3199
Mc-PEG8-Val-Ala-PABC
[66]
SC16.58-DL5
SC16.58
Delta-like protein 3 (DLL3)
SG3199
Mc-PEG8-Val-Ala-PABC
[66]
SC16.61-DL5
SC16.61
Delta-like protein 3 (DLL3)
SG3199
Mc-PEG8-Val-Ala-PABC
[66]
SC16.62-DL5
SC16.62
Delta-like protein 3 (DLL3)
SG3199
Mc-PEG8-Val-Ala-PABC
[66]
SC16.63-DL5
SC16.63
Delta-like protein 3 (DLL3)
SG3199
Mc-PEG8-Val-Ala-PABC
[66]
SC16.65-DL5
SC16.65
Delta-like protein 3 (DLL3)
SG3199
Mc-PEG8-Val-Ala-PABC
[66]
SC16.67-DL5
SC16.67
Delta-like protein 3 (DLL3)
SG3199
Mc-PEG8-Val-Ala-PABC
[66]
SC16.68-DL5
SC16.68
Delta-like protein 3 (DLL3)
SG3199
Mc-PEG8-Val-Ala-PABC
[66]
SC16.72-DL5
SC16.72
Delta-like protein 3 (DLL3)
SG3199
Mc-PEG8-Val-Ala-PABC
[66]
SC16.73-DL5
SC16.73
Delta-like protein 3 (DLL3)
SG3199
Mc-PEG8-Val-Ala-PABC
[66]
SC16.78-DL5
SC16.78
Delta-like protein 3 (DLL3)
SG3199
Mc-PEG8-Val-Ala-PABC
[66]
SC16.79-DL5
SC16.79
Delta-like protein 3 (DLL3)
SG3199
Mc-PEG8-Val-Ala-PABC
[66]
SC16.80-DL5
SC16.80
Delta-like protein 3 (DLL3)
SG3199
Mc-PEG8-Val-Ala-PABC
[66]
SC16.81-DL5
SC16.81
Delta-like protein 3 (DLL3)
SG3199
Mc-PEG8-Val-Ala-PABC
[66]
SC16.84-DL5
SC16.84
Delta-like protein 3 (DLL3)
SG3199
Mc-PEG8-Val-Ala-PABC
[66]
SC16.88-DL5
SC16.88
Delta-like protein 3 (DLL3)
SG3199
Mc-PEG8-Val-Ala-PABC
[66]
SC16.101-DL5
SC16.101
Delta-like protein 3 (DLL3)
SG3199
Mc-PEG8-Val-Ala-PABC
[66]
SC16.103-DL5
SC16.103
Delta-like protein 3 (DLL3)
SG3199
Mc-PEG8-Val-Ala-PABC
[66]
SC16.104-DL5
SC16.104
Delta-like protein 3 (DLL3)
SG3199
Mc-PEG8-Val-Ala-PABC
[66]
SC16.105-DL5
SC16.105
Delta-like protein 3 (DLL3)
SG3199
Mc-PEG8-Val-Ala-PABC
[66]
SC16.106-DL5
SC16.106
Delta-like protein 3 (DLL3)
SG3199
Mc-PEG8-Val-Ala-PABC
[66]
SC16.107-DL5
SC16.107
Delta-like protein 3 (DLL3)
SG3199
Mc-PEG8-Val-Ala-PABC
[66]
SC16.108-DL5
SC16.108
Delta-like protein 3 (DLL3)
SG3199
Mc-PEG8-Val-Ala-PABC
[66]
SC16.109-DL5
SC16.109
Delta-like protein 3 (DLL3)
SG3199
Mc-PEG8-Val-Ala-PABC
[66]
SC16.110-DL5
SC16.110
Delta-like protein 3 (DLL3)
SG3199
Mc-PEG8-Val-Ala-PABC
[66]
SC16.111-DL5
SC16.111
Delta-like protein 3 (DLL3)
SG3199
Mc-PEG8-Val-Ala-PABC
[66]
SC16.113-DL5
SC16.113
Delta-like protein 3 (DLL3)
SG3199
Mc-PEG8-Val-Ala-PABC
[66]
SC16.114-DL5
SC16.114
Delta-like protein 3 (DLL3)
SG3199
Mc-PEG8-Val-Ala-PABC
[66]
SC16.115-DL5
SC16.115
Delta-like protein 3 (DLL3)
SG3199
Mc-PEG8-Val-Ala-PABC
[66]
SC16.116-DL5
SC16.116
Delta-like protein 3 (DLL3)
SG3199
Mc-PEG8-Val-Ala-PABC
[66]
SC16.117-DL5
SC16.117
Delta-like protein 3 (DLL3)
SG3199
Mc-PEG8-Val-Ala-PABC
[66]
SC16.118-DL5
SC16.118
Delta-like protein 3 (DLL3)
SG3199
Mc-PEG8-Val-Ala-PABC
[66]
SC16.120-DL5
SC16.120
Delta-like protein 3 (DLL3)
SG3199
Mc-PEG8-Val-Ala-PABC
[66]
SC16.121-DL5
SC16.121
Delta-like protein 3 (DLL3)
SG3199
Mc-PEG8-Val-Ala-PABC
[66]
SC16.122-DL5
SC16.122
Delta-like protein 3 (DLL3)
SG3199
Mc-PEG8-Val-Ala-PABC
[66]
SC16.123-DL5
SC16.123
Delta-like protein 3 (DLL3)
SG3199
Mc-PEG8-Val-Ala-PABC
[66]
SC16.124-DL5
SC16.124
Delta-like protein 3 (DLL3)
SG3199
Mc-PEG8-Val-Ala-PABC
[66]
SC16.125-DL5
SC16.125
Delta-like protein 3 (DLL3)
SG3199
Mc-PEG8-Val-Ala-PABC
[66]
SC16.126-DL5
SC16.126
Delta-like protein 3 (DLL3)
SG3199
Mc-PEG8-Val-Ala-PABC
[66]
SC16.129-DL5
SC16.129
Delta-like protein 3 (DLL3)
SG3199
Mc-PEG8-Val-Ala-PABC
[66]
SC16.130-DL5
SC16.130
Delta-like protein 3 (DLL3)
SG3199
Mc-PEG8-Val-Ala-PABC
[66]
SC16.131-DL5
SC16.131
Delta-like protein 3 (DLL3)
SG3199
Mc-PEG8-Val-Ala-PABC
[66]
SC16.132-DL5
SC16.132
Delta-like protein 3 (DLL3)
SG3199
Mc-PEG8-Val-Ala-PABC
[66]
SC16.133-DL5
SC16.133
Delta-like protein 3 (DLL3)
SG3199
Mc-PEG8-Val-Ala-PABC
[66]
SC16.134-DL5
SC16.134
Delta-like protein 3 (DLL3)
SG3199
Mc-PEG8-Val-Ala-PABC
[66]
SC16.135-DL5
SC16.135
Delta-like protein 3 (DLL3)
SG3199
Mc-PEG8-Val-Ala-PABC
[66]
SC16.136-DL5
SC16.136
Delta-like protein 3 (DLL3)
SG3199
Mc-PEG8-Val-Ala-PABC
[66]
SC16.137-DL5
SC16.137
Delta-like protein 3 (DLL3)
SG3199
Mc-PEG8-Val-Ala-PABC
[66]
SC16.138-DL5
SC16.138
Delta-like protein 3 (DLL3)
SG3199
Mc-PEG8-Val-Ala-PABC
[66]
SC16.139-DL5
SC16.139
Delta-like protein 3 (DLL3)
SG3199
Mc-PEG8-Val-Ala-PABC
[66]
SC16.140-DL5
SC16.140
Delta-like protein 3 (DLL3)
SG3199
Mc-PEG8-Val-Ala-PABC
[66]
SC16.141-DL5
SC16.141
Delta-like protein 3 (DLL3)
SG3199
Mc-PEG8-Val-Ala-PABC
[66]
SC16.142-DL5
SC16.142
Delta-like protein 3 (DLL3)
SG3199
Mc-PEG8-Val-Ala-PABC
[66]
SC16.143-DL5
SC16.143
Delta-like protein 3 (DLL3)
SG3199
Mc-PEG8-Val-Ala-PABC
[66]
SC16.144-DL5
SC16.144
Delta-like protein 3 (DLL3)
SG3199
Mc-PEG8-Val-Ala-PABC
[66]
SC16.147-DL5
SC16.147
Delta-like protein 3 (DLL3)
SG3199
Mc-PEG8-Val-Ala-PABC
[66]
SC16.148-DL5
SC16.148
Delta-like protein 3 (DLL3)
SG3199
Mc-PEG8-Val-Ala-PABC
[66]
SC16.149-DL5
SC16.149
Delta-like protein 3 (DLL3)
SG3199
Mc-PEG8-Val-Ala-PABC
[66]
SC16.150-DL5
SC16.150
Delta-like protein 3 (DLL3)
SG3199
Mc-PEG8-Val-Ala-PABC
[66]
HuM25-S239C-PBD-E2
huM25-S239C
Leucine-rich repeat-containing protein 15 (LRRC15)
PBD dimer
Mc-Val-Ala
[67]
HuAD208.4.1-PBD-DAR2
huAD208.4.1
Leucine-rich repeat-containing protein 15 (LRRC15)
PBD dimer
Mc-Val-Ala
[67]
ABT-700 (S238C)-PBD
Telisotuzumab
Hepatocyte growth factor receptor (MET)
PBD dimer
Mc-Val-Ala
[68]
ADC Trast-14
Trastuzumab
Receptor tyrosine-protein kinase erbB-2 (ERBB2)
PBD dimer 3
Undisclosed
[69]
ADC Trast-11
Trastuzumab
Receptor tyrosine-protein kinase erbB-2 (ERBB2)
PBD dimer 3
Bis-BCN-modified Val-Cit-PABC linker 10
[69]
Anti-ApoD PBD
Anti-ApoD Anti-ody
Apolipoprotein D (APOD)
PBD dimer
Undisclosed
[70]
SNS-622-DUO
SNS-622
Aspartyl/asparaginyl beta-hydroxylase (ASPH)
Duocarmycin A
Mc-Val-Cit-PABC
[71]
DAB4-DuoDM
DAB4
Lupus La protein (SSB)
DEAEA duocarmycin
Mal-PEG4-Val-Cit-PABC
[72]
Sal5-DuoDM
Sal5
Epidermal growth factor receptor (EGFR); Receptor tyrosine-protein kinase erbB-3 (ERBB3)
DEAEA duocarmycin
Mal-PEG4-Val-Cit-PABC
[72]
ChDAB4-SG3249
Chimeric DAB4 (chDAB4)
Lupus La protein (SSB)
SG3199
Mal-PEG8-Val-Ala-PABC
[72]
B12-SG3249
B12
Envelope glycoprotein gp160 (env)
SG3199
Mal-PEG8-Val-Ala-PABC
[72]
Rituximab-DNA conjugate
Rituximab
B-lymphocyte antigen CD20 (MS4A1)
DNA mimics
Undisclosed
[73]
Cetuximab-DNA conjugate
Cetuximab
Epidermal growth factor receptor (EGFR)
DNA mimics
Undisclosed
[73]
Panitumumab-DNA conjugate
Panitumumab
Epidermal growth factor receptor (EGFR)
DNA mimics
Undisclosed
[73]
Trastuzumab-DNA conjugate
Trastuzumab
Receptor tyrosine-protein kinase erbB-2 (ERBB2)
DNA mimics
Undisclosed
[73]
OHPAS ADC-2
Trastuzumab
Receptor tyrosine-protein kinase erbB-2 (ERBB2)
SG2000
Ortho-hydroxy-protected aryl sulfate
[74]
OHPAS ADC-3
Trastuzumab
Receptor tyrosine-protein kinase erbB-2 (ERBB2)
seco-CBI-indole
Ortho-hydroxy-protected aryl sulfate
[74]
OHPAS ADC-4
Trastuzumab
Receptor tyrosine-protein kinase erbB-2 (ERBB2)
CBI-dimer-beta-Gal
Ortho-hydroxy-protected aryl sulfate
[74]
AF-GPL
Anti-ody fragment (AF)
Epidermal growth factor receptor (EGFR); Receptor tyrosine-protein kinase erbB-3 (ERBB3)
Gemcitabine and paclitaxel loaded liposome
Undisclosed
[75]
HmAb-C-DUBA
hmAb-C
CD276 antigen (CD276)
seco-DUBA
Mal-PEG2-Val-Cit-PABA-Cyclization Spacer
[76]
Alpha-HER2-Duo 405
Anti-HER2 mAb
Receptor tyrosine-protein kinase erbB-2 (ERBB2)
Duocarmycin 405
Undisclosed
[77]
WO2021044208A1 ADC6
Anti-ROR1 mAb C2E3
Inactive tyrosine-protein kinase transmembrane receptor ROR1 (ROR1)
SG2000
WO2021044208A1_ADC6 linker
[7]
WO2021044208A1 ADC7
Anti-ROR1 mAb C2E3
Inactive tyrosine-protein kinase transmembrane receptor ROR1 (ROR1)
SG2000
WO2021044208A1_ADC7 linker
[7]
WO2021044208A1 ADC8
Anti-ROR1 mAb C2E3
Inactive tyrosine-protein kinase transmembrane receptor ROR1 (ROR1)
SG2000
WO2021044208A1_ADC8 linker
[7]
WO2021044208A1 ADC 2A2-6
Anti-ROR1 mAb 2A2
Inactive tyrosine-protein kinase transmembrane receptor ROR1 (ROR1)
SG2000
WO2021044208A1_ADC 2A2-6 linker
[7]
WO2021044208A1 ADC 2A2-7
Anti-ROR1 mAb 2A2
Inactive tyrosine-protein kinase transmembrane receptor ROR1 (ROR1)
SG2000
WO2021044208A1_ADC 2A2-7 linker
[7]
WO2021044208A1 ADC AB4-1
Anti-ROR1 mAb 2A2
Inactive tyrosine-protein kinase transmembrane receptor ROR1 (ROR1)
SG2000
WO2021044208A1_ADC AB4-1 linker
[7]
WO2021044208A1 ADC AB4-6
Anti-ROR1 mAb AB4
Inactive tyrosine-protein kinase transmembrane receptor ROR1 (ROR1)
SG2000
WO2021044208A1_ADC AB4-6 linker
[7]
WO2021044208A1 ADC AB4-7
Anti-ROR1 mAb AB4
Inactive tyrosine-protein kinase transmembrane receptor ROR1 (ROR1)
SG2000
WO2021044208A1_ADC AB4-7 linker
[7]
WO2021044208A1 ADC A2F2-1
Anti-ROR1 mAb AB4
Inactive tyrosine-protein kinase transmembrane receptor ROR1 (ROR1)
SG2000
WO2021044208A1_ADC A2F2-1 linker
[7]
WO2021044208A1 ADC A2F2-6
Anti-ROR1 mAb A2F2
Inactive tyrosine-protein kinase transmembrane receptor ROR1 (ROR1)
SG2000
WO2021044208A1_ADC A2F2-6 linker
[7]
WO2021044208A1 ADC A2F2-7
Anti-ROR1 mAb A2F2
Inactive tyrosine-protein kinase transmembrane receptor ROR1 (ROR1)
SG2000
WO2021044208A1_ADC A2F2-7 linker
[7]
WO2021044208A1 ADC A2F3-1
Anti-ROR1 mAb A2F2
Inactive tyrosine-protein kinase transmembrane receptor ROR1 (ROR1)
SG2000
WO2021044208A1_ADC A2F3-1 linker
[7]
WO2021044208A1 ADC A2F3-6
Anti-ROR1 mAb A2F3
Inactive tyrosine-protein kinase transmembrane receptor ROR1 (ROR1)
SG2000
WO2021044208A1_ADC A2F3-6 linker
[7]
WO2021044208A1 ADC A2F3-7
Anti-ROR1 mAb A2F3
Inactive tyrosine-protein kinase transmembrane receptor ROR1 (ROR1)
SG2000
WO2021044208A1_ADC A2F3-7 linker
[7]
WO2021044208A1 ADC BA6-1
Anti-ROR1 mAb A2F3
Inactive tyrosine-protein kinase transmembrane receptor ROR1 (ROR1)
SG2000
WO2021044208A1_ADC BA6-1 linker
[7]
WO2021044208A1 ADC BA6-6
Anti-ROR1 mAb BA6
Inactive tyrosine-protein kinase transmembrane receptor ROR1 (ROR1)
SG2000
WO2021044208A1_ADC BA6-6 linker
[7]
WO2021044208A1 ADC BA6-7
Anti-ROR1 mAb BA6
Inactive tyrosine-protein kinase transmembrane receptor ROR1 (ROR1)
SG2000
WO2021044208A1_ADC BA6-7 linker
[7]
WO2021044208A1 ADC CC9-1
Anti-ROR1 mAb BA6
Inactive tyrosine-protein kinase transmembrane receptor ROR1 (ROR1)
SG2000
WO2021044208A1_ADC CC9-1 linker
[7]
WO2021044208A1 ADC CC9-6
Anti-ROR1 mAb CC9
Inactive tyrosine-protein kinase transmembrane receptor ROR1 (ROR1)
SG2000
WO2021044208A1_ADC CC9-6 linker
[7]
WO2021044208A1 ADC CC9-7
Anti-ROR1 mAb CC9
Inactive tyrosine-protein kinase transmembrane receptor ROR1 (ROR1)
SG2000
WO2021044208A1_ADC CC9-7 linker
[7]
WO2021044208A1 ADC DG6-1
Anti-ROR1 mAb CC9
Inactive tyrosine-protein kinase transmembrane receptor ROR1 (ROR1)
SG2000
WO2021044208A1_ADC DG6-1 linker
[7]
WO2021044208A1 ADC DG6-6
Anti-ROR1 mAb DG6
Inactive tyrosine-protein kinase transmembrane receptor ROR1 (ROR1)
SG2000
WO2021044208A1_ADC DG6-6 linker
[7]
WO2021044208A1 ADC DG6-7
Anti-ROR1 mAb DG6
Inactive tyrosine-protein kinase transmembrane receptor ROR1 (ROR1)
SG2000
WO2021044208A1_ADC DG6-7 linker
[7]
WO2021044208A1 ADC D2B12-1
Anti-ROR1 mAb DG6
Inactive tyrosine-protein kinase transmembrane receptor ROR1 (ROR1)
SG2000
WO2021044208A1_ADC D2B12-1 linker
[7]
WO2021044208A1 ADC D2B12-6
Anti-ROR1 mAb D2B12
Inactive tyrosine-protein kinase transmembrane receptor ROR1 (ROR1)
SG2000
WO2021044208A1_ADC D2B12-6 linker
[7]
WO2021044208A1 ADC D2B12-7
Anti-ROR1 mAb D2B12
Inactive tyrosine-protein kinase transmembrane receptor ROR1 (ROR1)
SG2000
WO2021044208A1_ADC D2B12-7 linker
[7]
WO2021044208A1 ADC A2F2 M1-1
Anti-ROR1 mAb D2B12
Inactive tyrosine-protein kinase transmembrane receptor ROR1 (ROR1)
SG2000
WO2021044208A1_ADC A2F2 M1-1 linker
[7]
WO2021044208A1 ADC A2F2 M1-7
Anti-ROR1 mAb A2F2 M1
Inactive tyrosine-protein kinase transmembrane receptor ROR1 (ROR1)
SG2000
WO2021044208A1_ADC A2F2 M1-7 linker
[7]
WO2013055987A1 Tmab-101
Trastuzumab
Receptor tyrosine-protein kinase erbB-2 (ERBB2)
SG2000
WO2013055987A1_Tmab-101 linker
[78]
WO2013055987A1 Tmab-102
Trastuzumab
Receptor tyrosine-protein kinase erbB-2 (ERBB2)
SG2000
WO2013055987A1_Tmab-102 linker
[78]
WO2013055987A1 xCD22-103
Anti-CD22 mAb xCD22
B-cell receptor CD22 (CD22)
SG2000
WO2013055987A1_xCD22-103 linker
[78]
WO2013055987A1 Tmab-104
Trastuzumab
Receptor tyrosine-protein kinase erbB-2 (ERBB2)
SG2000
WO2013055987A1_Tmab-104 linker
[78]
WO2013055987A1 Tmab-110
Trastuzumab
Receptor tyrosine-protein kinase erbB-2 (ERBB2)
SG2000
WO2013055987A1_Tmab-110 linker
[78]
Anti-c-Met IgG-OXA
Anti-MET mAb
Hepatocyte growth factor receptor (MET)
Oxaliplatin
Dipeptide-p-amidobenzyl alcohol linker
[79]
Dualtargeting lidamycin ADC
Undisclosed
Epidermal growth factor receptor (EGFR); Receptor tyrosine-protein kinase erbB-2 (ERBB2)
Lidamycin
Undisclosed
[80]
PF-06888667
Trastuzumab
Receptor tyrosine-protein kinase erbB-2 (ERBB2)
SW-163D
AcLys-Val-Cit-PABC-DMAE
[81]
Anti-FOLR1-Ala-Ala-IGN
Anti-FOLR1 mAb
Folate receptor alpha (FOLR1)
Indolinobenzodiazepine dimer
Ala-Ala dipeptide
[82]
Anti-FOLR1-Val-Gln-IGN
Anti-FOLR1 mAb
Folate receptor alpha (FOLR1)
Indolinobenzodiazepine dimer
Val-Gln dipeptide linker
[82]
Anti-EGFR-Ala-Ala-IGN
Anti-EGFR mAb
Epidermal growth factor receptor (EGFR)
Indolinobenzodiazepine dimer
Ala-Ala dipeptide
[82]
Anti-EGFR-Val-Gln-IGN
Anti-EGFR mAb
Epidermal growth factor receptor (EGFR)
Indolinobenzodiazepine dimer
Val-Gln dipeptide linker
[82]
Tb074-SG3376
Anti-HpHbR mAb Tb074
Haptoglobin-hemoglobin receptor (Tb06.28F21.220)
PBD dimer SG3552
Mal-PEG4
[83]
Tb085-SG3376
Anti-HpHbR mAb Tb085
Haptoglobin-hemoglobin receptor (Tb06.28F21.220)
PBD dimer SG3552
Mal-PEG4
[83]
CDX-0125-TEI
Anti-ALK mAb DX-0125
ALK tyrosine kinase receptor (ALK)
NMS-P945
Undisclosed
[84]
Anti-CLL-1-ds-PBD
Anti-CLL-1 THIOMAB Anti-ody
C-type lectin domain family 12 member A (CLEC12A)
SG2000
Undisclosed
[85]
HER2-HC-H-SS-PBD
Anti-HER2 mAb
Receptor tyrosine-protein kinase erbB-2 (ERBB2)
SG2000
H-disulfide linker
[86]
HER2-LC-H-SS-PBD
Anti-HER2 mAb
Receptor tyrosine-protein kinase erbB-2 (ERBB2)
SG2000
H-disulfide linker
[86]
HER2-HC-Me-SS-PBD
Anti-HER2 mAb
Receptor tyrosine-protein kinase erbB-2 (ERBB2)
SG2000
Me-disulfide linker
[86]
HER2-LC-Me-SS-PBD
Anti-HER2 mAb
Receptor tyrosine-protein kinase erbB-2 (ERBB2)
SG2000
Me-disulfide linker
[86]
Alpha-CD22-LC-K149C-10
Anti-CD22-LC-K149C
B-cell receptor CD22 (CD22)
seco-CBI-dimer
Mc-peptidomimetic based linker 10
[87]
Alpha-NaPi2b-LC-K149C-10
Anti-NaPi2b-LC-K149C
Sodium-dependent phosphate transport protein 2B (SLC34A2)
seco-CBI-dimer
Mc-peptidomimetic based linker 10
[87]
Alpha-Ly6E-LC-K149C-10
Anti-Ly6E-LC-K149C
Envelope glycoprotein D (Gd)
seco-CBI-dimer
Mc-peptidomimetic based linker 10
[87]
Alpha-gD-LC-K149C-10
Anti-gD-LC-K149C
Lymphocyte antigen 6E (LY6E)
seco-CBI-dimer
Mc-peptidomimetic based linker 10
[87]
Alpha-CD22-LC-K149C-11
Anti-CD22-LC-K149C
B-cell receptor CD22 (CD22)
seco-CBI-dimer
Mal-PEG2
[87]
Alpha-NaPi2b-LC-K149C-11
Anti-NaPi2b-LC-K149C
Sodium-dependent phosphate transport protein 2B (SLC34A2)
seco-CBI-dimer
Mal-PEG2
[87]
Alpha-Ly6E-LC-K149C-11
Anti-Ly6E-LC-K149C
Lymphocyte antigen 6E (LY6E)
seco-CBI-dimer
Mal-PEG2
[87]
Alpha-CD22-LC-V205C-10
Anti-CD22-LC-V205C
B-cell receptor CD22 (CD22)
seco-CBI-dimer
Mc-peptidomimetic based linker 10
[87]
Alpha-CD22-HC-A140C-10
Anti-CD22-HC-A140C
B-cell receptor CD22 (CD22)
seco-CBI-dimer
Mc-peptidomimetic based linker 10
[87]
Alpha-CD22-HC-A140C-11
Anti-CD22-HC-A140C
B-cell receptor CD22 (CD22)
seco-CBI-dimer
Mc-PEG2
[87]
Alpha-CD22-LC-K149C-12
Anti-CD22-LC-K149C
B-cell receptor CD22 (CD22)
Seco-CBI-dimer 12
Mc-peptidomimetic based linker 12
[87]
Alpha-gD-LC-K149C-12
Anti-gD-LC-K149C
Envelope glycoprotein D (Gd)
Seco-CBI-dimer 12
Mc-peptidomimetic based linker 12
[87]
HD12-SG3249
Anti-MET mAb hD12
Hepatocyte growth factor receptor (MET)
PBD dimer SG3249
Mal-PEG8-Val-Ala-PABC
[88]
HD12-SG3259
Anti-MET mAb hD12
Hepatocyte growth factor receptor (MET)
PBD dimer SG3259
Mal-PEG8-Val-Ala-PABC
[88]
HD12-SG3315
Anti-MET mAb hD12
Hepatocyte growth factor receptor (MET)
PBD dimer SG3315
Mal-PEG8-Val-Ala-PABC
[88]
HD12-SG3246
Anti-MET mAb hD12
Hepatocyte growth factor receptor (MET)
PBD dimer SG3246
Mal-PEG8-Val-Ala-PABC
[88]
HD12-SG3227
Anti-MET mAb hD12
Hepatocyte growth factor receptor (MET)
PBD dimer SG3227
Mal-PEG8-Val-Ala-PABC
[88]
ABBV-322
Depatuxizumab S238C
Epidermal growth factor receptor (EGFR)
PBD dimer
Mc-Val-Ala
[89]
FOLR1-ADC 13a
Anti-FOLR1 mAb
Folate receptor alpha (FOLR1)
PBD dimer 13a
Adipic acid-Val-Ala-PABC
[90]
FOLR1-ADC 13b
Anti-FOLR1 mAb
Folate receptor alpha (FOLR1)
PBD dimer 13b
Adipic acid-Val-Ala-PABC
[90]
FOLR1-ADC 13c
Anti-FOLR1 mAb
Folate receptor alpha (FOLR1)
PBD dimer 13c
Adipic acid-Val-Ala-PABC
[90]
EGFR-ADC 13a
Anti-EGFR mAb
Epidermal growth factor receptor (EGFR)
PBD dimer 14a
Adipic acid-Val-Ala-PABC
[90]
EGFR-ADC 13b
Anti-EGFR mAb
Epidermal growth factor receptor (EGFR)
PBD dimer 14b
Adipic acid-Val-Ala-PABC
[90]
EGFR-ADC 13c
Anti-EGFR mAb
Epidermal growth factor receptor (EGFR)
PBD dimer 14c
Adipic acid-Val-Ala-PABC
[90]
FOLR1-ADC 15
Anti-FOLR1 mAb
Folate receptor alpha (FOLR1)
PBD dimer 13c
Adipic acid-Val-CIt-PABC
[90]
Anti-BCMA 15B2GL-SG3249
Anti-BCMA antibody 15B2GL
Tumor necrosis factor receptor superfamily member 17 (TNFRSF17)
SG3199
CL2A
[91]
Anti-BCMA 15B2WT-SG3249
Anti-BCMA antibody 15B2WT
Tumor necrosis factor receptor superfamily member 17 (TNFRSF17)
SG3199
CL2A
[91]
Anti-BCMA I09-SG3249
Anti-BCMA antibody I09
Tumor necrosis factor receptor superfamily member 17 (TNFRSF17)
SG3199
CL2A
[91]
Anti-BCMA L15-SG3249
Anti-BCMA antibody L15
Tumor necrosis factor receptor superfamily member 17 (TNFRSF17)
SG3199
CL2A
[91]
Anti-BCMA M02-SG3249
Anti-BCMA antibody M02
Tumor necrosis factor receptor superfamily member 17 (TNFRSF17)
SG3199
CL2A
[91]
Anti-BCMA N22-SG3249
Anti-BCMA antibody N22
Tumor necrosis factor receptor superfamily member 17 (TNFRSF17)
SG3199
CL2A
[91]
Anti-BCMA P10-SG3249
Anti-BCMA antibody P10
Tumor necrosis factor receptor superfamily member 17 (TNFRSF17)
SG3199
CL2A
[91]
Anti-BCMA J6M0-SG3249
Anti-BCMA antibody J6M0
Tumor necrosis factor receptor superfamily member 17 (TNFRSF17)
SG3199
CL2A
[91]
Anti-BCMA R347-SG3249
Anti-BCMA antibody R347
Tumor necrosis factor receptor superfamily member 17 (TNFRSF17)
SG3199
CL2A
[91]
SYD998
Anti-PSMA mAb wt
Glutamate carboxypeptidase 2 (FOLH1)
seco-DUBA
Mal-PEG2-Val-Cit-PABA-Cyclization Spacer
[92]
SYD1091
Anti-PSMA mAb wt HC S41C
Glutamate carboxypeptidase 2 (FOLH1)
seco-DUBA
Mal-PEG2-Val-Cit-PABA-Cyclization Spacer
[92]
SYD1035
Anti-PSMA mAb wt HC T120C
Glutamate carboxypeptidase 2 (FOLH1)
seco-DUBA
Mal-PEG2-Val-Cit-PABA-Cyclization Spacer
[92]
WO2015177360A1 ADC-HC152
Anti-PSMA mAb wt HC E152C
Glutamate carboxypeptidase 2 (FOLH1)
seco-DUBA
Mal-PEG2-Val-Cit-PABA-Cyclization Spacer
[92]
WO2015177360A1 ADC-HC153
Anti-PSMA mAb wt HC P153C
Glutamate carboxypeptidase 2 (FOLH1)
seco-DUBA
Mal-PEG2-Val-Cit-PABA-Cyclization Spacer
[92]
WO2015177360A1 ADC-HC236
Anti-PSMA mAb wt HC G236C
Glutamate carboxypeptidase 2 (FOLH1)
seco-DUBA
Mal-PEG2-Val-Cit-PABA-Cyclization Spacer
[92]
WO2015177360A1 ADC-HC247
Anti-PSMA mAb wt HC P247C
Glutamate carboxypeptidase 2 (FOLH1)
seco-DUBA
Mal-PEG2-Val-Cit-PABA-Cyclization Spacer
[92]
WO2015177360A1 ADC-HC339
Anti-PSMA mAb wt HC A339C
Glutamate carboxypeptidase 2 (FOLH1)
seco-DUBA
Mal-PEG2-Val-Cit-PABA-Cyclization Spacer
[92]
WO2015177360A1 ADC-HC375
Anti-PSMA mAb wt HC S375C
Glutamate carboxypeptidase 2 (FOLH1)
seco-DUBA
Mal-PEG2-Val-Cit-PABA-Cyclization Spacer
[92]
WO2015177360A1 ADC-HC376
Anti-PSMA mAb wt HC D376C
Glutamate carboxypeptidase 2 (FOLH1)
seco-DUBA
Mal-PEG2-Val-Cit-PABA-Cyclization Spacer
[92]
WO2015177360A1 ADC-HC41-120
Anti-PSMA mAb wt HC S41C/T120C
Glutamate carboxypeptidase 2 (FOLH1)
seco-DUBA
Mal-PEG2-Val-Cit-PABA-Cyclization Spacer
[92]
WO2015177360A1 ADC-HC41-375
Anti-PSMA mAb wt HC S41C/S375C
Glutamate carboxypeptidase 2 (FOLH1)
seco-DUBA
Mal-PEG2-Val-Cit-PABA-Cyclization Spacer
[92]
WO2015177360A1 ADC-LC40
Anti-PSMA mAb wt LC V205C
Glutamate carboxypeptidase 2 (FOLH1)
seco-DUBA
Mal-PEG2-Val-Cit-PABA-Cyclization Spacer
[92]
WO2015177360A1 ADC-LC154
Anti-PSMA mAb wt LC P40C
Glutamate carboxypeptidase 2 (FOLH1)
seco-DUBA
Mal-PEG2-Val-Cit-PABA-Cyclization Spacer
[92]
WO2015177360A1 ADC-LC165
Anti-PSMA mAb wt LC L154C
Glutamate carboxypeptidase 2 (FOLH1)
seco-DUBA
Mal-PEG2-Val-Cit-PABA-Cyclization Spacer
[92]
WO2015177360A1 ADC-LC205
Anti-PSMA mAb wt LC E165C
Glutamate carboxypeptidase 2 (FOLH1)
seco-DUBA
Mal-PEG2-Val-Cit-PABA-Cyclization Spacer
[92]
WO2015177360A1 ADC-LC41
Anti-PSMA mAb wt LC G41C
Glutamate carboxypeptidase 2 (FOLH1)
seco-DUBA
Mal-PEG2-Val-Cit-PABA-Cyclization Spacer
[92]
WO2015177360A1 ADC-LC157
Anti-PSMA mAb wt LC G157C
Glutamate carboxypeptidase 2 (FOLH1)
seco-DUBA
Mal-PEG2-Val-Cit-PABA-Cyclization Spacer
[92]
WO2015177360A1 ADC-H8-wt
Anti-5T4 mAb H8 wt
Trophoblast glycoprotein (TPBG)
seco-DUBA
Mal-PEG2-Val-Cit-PABA-Cyclization Spacer
[92]
WO2015177360A1 ADC-LC109
Anti-PSMA mAb wt LC T109C
Glutamate carboxypeptidase 2 (FOLH1)
seco-DUBA
Mal-PEG2-Val-Cit-PABA-Cyclization Spacer
[92]
WO2015177360A1 ADC-H8-HC40
Anti-5T4 mAb H8 S40C
Trophoblast glycoprotein (TPBG)
seco-DUBA
Mal-PEG2-Val-Cit-PABA-Cyclization Spacer
[92]
WO2015177360A1 ADC-H8-HC41
Anti-5T4 mAb H8 P41C
Trophoblast glycoprotein (TPBG)
seco-DUBA
Mal-PEG2-Val-Cit-PABA-Cyclization Spacer
[92]
WO2015177360A1 ADC-Natalizumab S375C
Natalizumab S375C
Integrin alpha-4 (ITGA4)
seco-DUBA
Mal-PEG2-Val-Cit-PABA-Cyclization Spacer
[92]
Trastuzumab-Compound 43
Trastuzumab
Receptor tyrosine-protein kinase erbB-2 (ERBB2)
PBD dimer
Trastuzumab-Compound 43 linker
[93]
Pertuzumab-Compound 43
Pertuzumab
Receptor tyrosine-protein kinase erbB-2 (ERBB2)
PBD dimer
Pertuzumab-Compound 43 linker
[93]
Rituximab-Compound 43
Rituximab
B-lymphocyte antigen CD20 (MS4A1)
PBD dimer
Rituximab-Compound 43 linker
[93]
Alemtuzumab-Compound 43
Alemtuzumab
CAMPATH-1 antigen (CD52)
PBD dimer
Alemtuzumab-Compound 43 linker
[93]
Bevacizumab-Compound 43
Bevacizumab
Vascular endothelial growth factor A (VEGFA)
PBD dimer
Bevacizumab-Compound 43 linker
[93]
Adalimumab-Compound 43
Adalimumab
Tumor necrosis factor (TNF)
PBD dimer
Adalimumab-Compound 43 linker
[93]
Cetuximab-Compound 43
Cetuximab
Epidermal growth factor receptor (EGFR)
PBD dimer
Cetuximab-Compound 43 linker
[93]
Amatuximab-Compound 43
Amatuximab
Mesothelin (MSLN)
PBD dimer
Amatuximab-Compound 43 linker
[93]
Blinatumomab-Compound 43
Blinatumomab
B-lymphocyte antigen CD19 (CD19); T-cell surface glycoprotein CD3 delta chain (CD3;TPBG)
PBD dimer
Blinatumomab-Compound 43 linker
[93]
Brentuximab-Compound 43
Brentuximab
Tumor necrosis factor receptor superfamily member 8 (TNFRSF8)
PBD dimer
Brentuximab-Compound 43 linker
[93]
Sacituzumab-Compound 43
Sacituzumab
Tumor-associated calcium signal transducer 2 (TACSTD2)
PBD dimer
Sacituzumab-Compound 43 linker
[93]
Panitumumab-Compound 43
Panitumumab
Epidermal growth factor receptor (EGFR)
PBD dimer
Panitumumab-Compound 43 linker
[93]
Nimotuzumab-Compound 43
Nimotuzumab
Epidermal growth factor receptor (EGFR)
PBD dimer
Nimotuzumab-Compound 43 linker
[93]
Gemtuzumab-Compound 43
Gemtuzumab
Myeloid cell surface antigen CD33 (CD33)
PBD dimer
Gemtuzumab-Compound 43 linker
[93]
Golimumab-Compound 43
Golimumab
Tumor necrosis factor (TNF)
PBD dimer
Golimumab-Compound 43 linker
[93]
Ibritumomab-Compound 43
Ibritumomab
B-lymphocyte antigen CD20 (MS4A1)
PBD dimer
Ibritumomab-Compound 43 linker
[93]
Infliximab-Compound 43
Infliximab
Tumor necrosis factor (TNF)
PBD dimer
Infliximab-Compound 43 linker
[93]
Ipilimumab-Compound 43
Ipilimumab
Cytotoxic T-lymphocyte protein 4 (CTLA4)
PBD dimer
Ipilimumab-Compound 43 linker
[93]
Ofatumumab-Compound 43
Ofatumumab
B-lymphocyte antigen CD20 (MS4A1)
PBD dimer
Ofatumumab-Compound 43 linker
[93]
Tositumomab-Compound 43
Tositumomab
B-lymphocyte antigen CD20 (MS4A1)
PBD dimer
Tositumomab-Compound 43 linker
[93]
Trastuzumab-Compound 49
Trastuzumab
Receptor tyrosine-protein kinase erbB-2 (ERBB2)
PBD dimer
Trastuzumab-Compound 49 linker
[93]
Pertuzumab-Compound 49
Pertuzumab
Receptor tyrosine-protein kinase erbB-2 (ERBB2)
PBD dimer
Pertuzumab-Compound 49 linker
[93]
Rituximab-Compound 49
Rituximab
B-lymphocyte antigen CD20 (MS4A1)
PBD dimer
Rituximab-Compound 49 linker
[93]
Alemtuzumab-Compound 49
Alemtuzumab
CAMPATH-1 antigen (CD52)
PBD dimer
Alemtuzumab-Compound 49 linker
[93]
Bevacizumab-Compound 49
Bevacizumab
Vascular endothelial growth factor A (VEGFA)
PBD dimer
Bevacizumab-Compound 49 linker
[93]
Adalimumab-Compound 49
Adalimumab
Tumor necrosis factor (TNF)
PBD dimer
Adalimumab-Compound 49 linker
[93]
Cetuximab-Compound 49
Cetuximab
Epidermal growth factor receptor (EGFR)
PBD dimer
Cetuximab-Compound 49 linker
[93]
Amatuximab-Compound 49
Amatuximab
Mesothelin (MSLN)
PBD dimer
Amatuximab-Compound 49 linker
[93]
Blinatumomab-Compound 49
Blinatumomab
B-lymphocyte antigen CD19 (CD19); T-cell surface glycoprotein CD3 delta chain (CD3;TPBG)
PBD dimer
Blinatumomab-Compound 49 linker
[93]
Brentuximab-Compound 49
Brentuximab
Tumor necrosis factor receptor superfamily member 8 (TNFRSF8)
PBD dimer
Brentuximab-Compound 49 linker
[93]
Sacituzumab-Compound 49
Sacituzumab
Tumor-associated calcium signal transducer 2 (TACSTD2)
PBD dimer
Sacituzumab-Compound 49 linker
[93]
Panitumumab-Compound 49
Panitumumab
Epidermal growth factor receptor (EGFR)
PBD dimer
Panitumumab-Compound 49 linker
[93]
Nimotuzumab-Compound 49
Nimotuzumab
Epidermal growth factor receptor (EGFR)
PBD dimer
Nimotuzumab-Compound 49 linker
[93]
Gemtuzumab-Compound 49
Gemtuzumab
Myeloid cell surface antigen CD33 (CD33)
PBD dimer
Gemtuzumab-Compound 49 linker
[93]
Golimumab-Compound 49
Golimumab
Tumor necrosis factor (TNF)
PBD dimer
Golimumab-Compound 49 linker
[93]
Ibritumomab-Compound 49
Ibritumomab
B-lymphocyte antigen CD20 (MS4A1)
PBD dimer
Ibritumomab-Compound 49 linker
[93]
Infliximab-Compound 49
Infliximab
Tumor necrosis factor (TNF)
PBD dimer
Infliximab-Compound 49 linker
[93]
Ipilimumab-Compound 49
Ipilimumab
Cytotoxic T-lymphocyte protein 4 (CTLA4)
PBD dimer
Ipilimumab-Compound 49 linker
[93]
Ofatumumab-Compound 49
Ofatumumab
B-lymphocyte antigen CD20 (MS4A1)
PBD dimer
Ofatumumab-Compound 49 linker
[93]
Tositumomab-Compound 49
Tositumomab
B-lymphocyte antigen CD20 (MS4A1)
PBD dimer
Tositumomab-Compound 49 linker
[93]
Trastuzumab-Compound 74
Trastuzumab
Receptor tyrosine-protein kinase erbB-2 (ERBB2)
PBD dimer
Trastuzumab-Compound 74 linker
[93]
Pertuzumab-Compound 74
Pertuzumab
Receptor tyrosine-protein kinase erbB-2 (ERBB2)
PBD dimer
Pertuzumab-Compound 74 linker
[93]
Rituximab-Compound 74
Rituximab
B-lymphocyte antigen CD20 (MS4A1)
PBD dimer
Rituximab-Compound 74 linker
[93]
Alemtuzumab-Compound 74
Alemtuzumab
CAMPATH-1 antigen (CD52)
PBD dimer
Alemtuzumab-Compound 74 linker
[93]
Bevacizumab-Compound 74
Bevacizumab
Vascular endothelial growth factor A (VEGFA)
PBD dimer
Bevacizumab-Compound 74 linker
[93]
Adalimumab-Compound 74
Adalimumab
Tumor necrosis factor (TNF)
PBD dimer
Adalimumab-Compound 74 linker
[93]
Cetuximab-Compound 74
Cetuximab
Epidermal growth factor receptor (EGFR)
PBD dimer
Cetuximab-Compound 74 linker
[93]
Amatuximab-Compound 74
Amatuximab
Mesothelin (MSLN)
PBD dimer
Amatuximab-Compound 74 linker
[93]
Blinatumomab-Compound 74
Blinatumomab
B-lymphocyte antigen CD19 (CD19); T-cell surface glycoprotein CD3 delta chain (CD3;TPBG)
PBD dimer
Blinatumomab-Compound 74 linker
[93]
Brentuximab-Compound 74
Brentuximab
Tumor necrosis factor receptor superfamily member 8 (TNFRSF8)
PBD dimer
Brentuximab-Compound 74 linker
[93]
Sacituzumab-Compound 74
Sacituzumab
Tumor-associated calcium signal transducer 2 (TACSTD2)
PBD dimer
Sacituzumab-Compound 74 linker
[93]
Panitumumab-Compound 74
Panitumumab
Epidermal growth factor receptor (EGFR)
PBD dimer
Panitumumab-Compound 74 linker
[93]
Nimotuzumab-Compound 74
Nimotuzumab
Epidermal growth factor receptor (EGFR)
PBD dimer
Nimotuzumab-Compound 74 linker
[93]
Gemtuzumab-Compound 74
Gemtuzumab
Myeloid cell surface antigen CD33 (CD33)
PBD dimer
Gemtuzumab-Compound 74 linker
[93]
Golimumab-Compound 74
Golimumab
Tumor necrosis factor (TNF)
PBD dimer
Golimumab-Compound 74 linker
[93]
Ibritumomab-Compound 74
Ibritumomab
B-lymphocyte antigen CD20 (MS4A1)
PBD dimer
Ibritumomab-Compound 74 linker
[93]
Infliximab-Compound 74
Infliximab
Tumor necrosis factor (TNF)
PBD dimer
Infliximab-Compound 74 linker
[93]
Ipilimumab-Compound 74
Ipilimumab
Cytotoxic T-lymphocyte protein 4 (CTLA4)
PBD dimer
Ipilimumab-Compound 74 linker
[93]
Ofatumumab-Compound 74
Ofatumumab
B-lymphocyte antigen CD20 (MS4A1)
PBD dimer
Ofatumumab-Compound 74 linker
[93]
Tositumomab-Compound 74
Tositumomab
B-lymphocyte antigen CD20 (MS4A1)
PBD dimer
Tositumomab-Compound 74 linker
[93]
Anti-MSL1 mAb-Compound 43
Anti-MSL1 mAb
Male-specific lethal 1 homolog (MSL1)
PBD dimer
Anti-MSL1 mAb-Compound 43 linker
[93]
Anti-CD59 mAb-Compound 43
Anti-CD59 mAb
CD59 glycoprotein (CD59)
PBD dimer
Anti-CD59 mAb-Compound 43 linker
[93]
Anti-HER2 mAb-Compound 43
Anti-HER2 mAb
Receptor tyrosine-protein kinase erbB-2 (ERBB2)
PBD dimer
Anti-HER2 mAb-Compound 43 linker
[93]
Anti-MSL1 mAb-Compound 49
Anti-MSL1 mAb
Male-specific lethal 1 homolog (MSL1)
PBD dimer
Anti-MSL1 mAb-Compound 49 linker
[93]
Anti-CD59 mAb-Compound 49
Anti-CD59 mAb
CD59 glycoprotein (CD59)
PBD dimer
Anti-CD59 mAb-Compound 49 linker
[93]
Anti-HER2 mAb-Compound 49
Anti-HER2 mAb
Receptor tyrosine-protein kinase erbB-2 (ERBB2)
PBD dimer
Anti-HER2 mAb-Compound 49 linker
[93]
Anti-MSL1 mAb-Compound 74
Anti-MSL1 mAb
Male-specific lethal 1 homolog (MSL1)
PBD dimer
Anti-MSL1 mAb-Compound 74 linker
[93]
Anti-CD59 mAb-Compound 74
Anti-CD59 mAb
CD59 glycoprotein (CD59)
PBD dimer
Anti-CD59 mAb-Compound 74 linker
[93]
Anti-HER2 mAb-Compound 74
Anti-HER2 mAb
Receptor tyrosine-protein kinase erbB-2 (ERBB2)
PBD dimer
Anti-HER2 mAb-Compound 74 linker
[93]
Investigative
Click To Hide/Show 45 ADC Related to This Stage
ADC Info ADC Name Antibody Antigen Payload Linker Ref
Isotype-SG3249
undisclosed
undisclosed
SG3199
Undisclosed
[94]
Isotype-SG3376
undisclosed
undisclosed
SG3199
Undisclosed
[94]
ADC based on linker 1 (DAR 2)
undisclosed
Staphylococcus aureus bacteria
Mitomycin C
Undisclosed
[95]
ADC based on linker 1 (DAR 5)
undisclosed
Staphylococcus aureus bacteria
Mitomycin C
Undisclosed
[95]
ADC based on linker 2 (DAR 2)
undisclosed
Staphylococcus aureus bacteria
Mitomycin C
Undisclosed
[95]
37290045 ADC based on linker 2 (DAR 5)
undisclosed
Staphylococcus aureus bacteria
Mitomycin C
Undisclosed
[95]
39757732 ADC2
Ab-2
Undisclosed
PBD dimer
D2 Linker
[96]
CD117-ADC
undisclosed
Mast/stem cell growth factor receptor Kit (KIT)
SG3199
Mal-PEG8-Val-Ala-PABC
[97]
39870768 20D9h3-DUBA
20D9h3
Receptor-type tyrosine-protein kinase FLT3 (FLT3)
seco-DUBA
Undisclosed
[98]
anti TRBC1-SG3249
undisclosed
T cell receptor beta-chain constant region 1 (TRBC1)
SG3199
CL2A
[99]
Chimeric anti TRBC1-SG3249
undisclosed
T cell receptor beta-chain constant region 1 (TRBC1)
SG3199
CL2A
[99]
KK2845
TIM-3Ab
TIM3
SG3199 (SC-DR002)
Mal-PEG8-Val-Ala-PABC
[100]
KM8047-SG3249
KM8047
Undisclosed
SG3199
Undisclosed
[100]
CD33-ADC
h2H12
Myeloid cell surface antigen CD33 (CD33)
SG3199
Undisclosed
[100]
QLS5132
Anti-CLDN6 antibody
CLDN6
QLS6916
A cleavable linker
[101]
AM E3-SG3249
AM E3
Cytokine receptor-like factor 2 (CRLF2)
SG3199
Mal-PEG8-Val-Ala-PABC
[102]
NZ761939B 15B2GL-SG3249
15B2GL
Tumor necrosis factor receptor superfamily member 17 (TNFRSF17)
SG3199
CL2A
[103]
I09-SG3249
I09
Tumor necrosis factor receptor superfamily member 17 (TNFRSF17)
SG3199
CL2A
[103]
L15-SG3249
L15
Tumor necrosis factor receptor superfamily member 17 (TNFRSF17)
SG3199
CL2A
[103]
M02-SG3249
M02
Tumor necrosis factor receptor superfamily member 17 (TNFRSF17)
SG3199
CL2A
[103]
N22-SG3249
N22
Tumor necrosis factor receptor superfamily member 17 (TNFRSF17)
SG3199
CL2A
[103]
P10-SG3249
P10
Tumor necrosis factor receptor superfamily member 17 (TNFRSF17)
SG3199
CL2A
[103]
Trastuzumab-LD1
Trastuzumab
Receptor tyrosine-protein kinase erbB-2 (ERBB2)
seco-DUBA
Trastuzumab-LD1-LINKER
[104]
Trastuzumab-LD3
Trastuzumab
Receptor tyrosine-protein kinase erbB-2 (ERBB2)
seco-DUBA
Trastuzumab-LD3-LINKER
[104]
Trastuzumab-LD4
Trastuzumab
Receptor tyrosine-protein kinase erbB-2 (ERBB2)
seco-DUBA
Trastuzumab-LD1-LINKER
[104]
Trastuzumab-LD5
Trastuzumab
Receptor tyrosine-protein kinase erbB-2 (ERBB2)
seco-DUBA
Trastuzumab-LD1-LINKER
[104]
Trastuzumab-LD6
Trastuzumab
Receptor tyrosine-protein kinase erbB-2 (ERBB2)
seco-DUBA
Trastuzumab-LD1-LINKER
[104]
PSMA-HC41-LD36
Anti-PSMA-HC41
Glutamate carboxypeptidase 2 (FOLH1)
seco-DUBA
PSMA-HC41-LD36 LINKER
[104]
JP2024177330A5 18G3-CPI
18G3
Interleukin-3 receptor subunit alpha (IL3RA)
Cyclopropylpyrroloindoline (CPI) payload
Undisclosed
[105]
JP2024177330A5 16D6-CPI
16D6
Interleukin-3 receptor subunit alpha (IL3RA)
Cyclopropylpyrroloindoline (CPI) payload
Undisclosed
[105]
JP2024177330A5 3D1-CPI
3D1
Interleukin-3 receptor subunit alpha (IL3RA)
Cyclopropylpyrroloindoline (CPI) payload
Undisclosed
[105]
JP2024177330A5 20D7-CPI
20D7
Interleukin-3 receptor subunit alpha (IL3RA)
Cyclopropylpyrroloindoline (CPI) payload
Undisclosed
[105]
ZA202500202A 2188-D04-Y180-LP9
2188-D04-Y180
Inactive tyrosine-protein kinase transmembrane receptor ROR1 (ROR1)
PBD dimer
DBCO-PEG4-VA
[106]
IN202417103159A 2188-D04-Yl80-LP9
undisclosed
Inactive tyrosine-protein kinase transmembrane receptor ROR1 (ROR1)
PBD
Undisclosed
[107]
anti-TRBC1-SG3249
undisclosed
T-cell receptor beta constant region (TRBC)
SG3199
CL2A
[108]
Chimeric anti-TRBC1-SG3249
undisclosed
T-cell receptor beta constant region (TRBC)
SG3199
CL2A
[108]
DBCO-vc-seco DUBA
HuSS1
Undisclosed
seco-DUBA
EP4161582A4+DBCO-vc-seco DUBA+Linker
[109]
DBCO-DTPA
HuSS1
Undisclosed
seco-DUBA
EP4161582A4+DBCO-DTPA+Linker
[109]
HuCL47-B1
HuCL47
Interleukin-13 receptor subunit alpha-2 (IL13RA2)
B4 Payload
US20230285580A1 B12-B2 linker
[110]
US20230285580A1 B12-B1
B12
Undisclosed
B4 Payload
US20230285580A1 B12-B2 linker
[110]
HuCL47-B6
HuCL47
Interleukin-13 receptor subunit alpha-2 (IL13RA2)
B4 Payload
US20230285580A1 B12-B6 linker
[110]
US20230285580A1 B12-B6
B12
Undisclosed
B4 Payload
US20230285580A1 B12-B6 linker
[110]
WO2024181570A1 ADC7
Antibody 1
Syndecan-1 (SDC1)
PBD
Mc-Val-Ala
[111]
CD45-ADC (37567393)
anti-mouse CD45.2
Receptor-type tyrosine-protein phosphatase C (PTPRC)
SG3199
Mal-PEG8-Val-Ala-PABC
[112]
ITC-6146RO
Anti-B7H3 antibody
B7-H3
Duocarmycin derivative
Self-immolative OHPAS linker
References
Ref 1 Inotuzumab Ozogamicin: First Global Approval
Ref 2 Approval summary: gemtuzumab ozogamicin in relapsed acute myeloid leukemia
Ref 3 A Study of SC-005 in Subjects With Triple Negative Breast Cancer (TNBC)
Ref 4 Anti?tissue factor antibody?mediated immuno?SPECT imaging of tissue factor expression in mouse models of pancreatic cancer. Oncol Rep. 2019 Apr;41(4):2371-2378. doi: 10.3892/or.2019.7017. Epub 2019 Feb 14.
Ref 5 Evaluation of 111In-DOTA-5D3, a Surrogate SPECT Imaging Agent for Radioimmunotherapy of Prostate-Specific Membrane Antigen. J Nucl Med. 2019 Mar;60(3):400-406. doi: 10.2967/jnumed.118.214403. Epub 2018 Sep 20.
Ref 6 Design, Synthesis, and Bioevaluation of a Novel Hybrid Molecular Pyrrolobenzodiazepine-Anthracenecarboxyimide as a Payload for Antibody-Drug Conjugate. J Med Chem. 2022 Sep 8;65(17):11679-11702. doi: 10.1021/acs.jmedchem.2c00471. Epub 2022 Aug 18.
Ref 7 Antibody-drug conjugate comprising antibody against human ror1, and use for the same; 2021-04-01.
Ref 8 Design and characterization of homogenous antibody-drug conjugates with a drug-to-antibody ratio of one prepared using an engineered antibody and a dual-maleimide pyrrolobenzodiazepine dimer. MAbs. 2019 Apr;11(3):500-515.
Ref 9 Synthesis and evaluation of pyrrolobenzodiazepine dimer antibody-drug conjugates with dual -glucuronide and dipeptide triggers. Eur J Med Chem. 2019 Oct 1;179:591-607.
Ref 10 A recombinant scFv antibody-based fusion protein that targets EGFR associated with IMPDH2 downregulation and its drug conjugate show therapeutic efficacy against esophageal cancer. Drug Deliv. 2022 Dec;29(1):1243-1256.
Ref 11 A new class of DNA sequence-selective G-A cross-linking antibody-drug conjugate (ADC) payloads. Cancer Res (2022) 82 (12_Supplement): 1749.
Ref 12 A GPC2 antibody-drug conjugate is efficacious against neuroblastoma and small-cell lung cancer via binding a conformational epitope. Cell Rep Med. 2021 Jul 21;2(7):100344.
Ref 13 Synthesis and in vitro evaluation of SG3227, a pyrrolobenzodiazepine dimer antibody-drug conjugate payload based on sibiromycin. Bioorg Med Chem Lett. 2017 Mar 1;27(5):1154-1158.
Ref 14 Design and Synthesis of Tesirine, a Clinical Antibody-Drug Conjugate Pyrrolobenzodiazepine Dimer Payload. ACS Med Chem Lett. 2016 May 24;7(11):983-987.
Ref 15 Antibody drug conjugates, targeting cancer-expressed EGFR, exhibit potent and specific antitumor activity. Biomed Pharmacother. 2023 Jan;157:114047.
Ref 16 An Anti-CD22-seco-CBI-Dimer Antibody-Drug Conjugate (ADC) for the Treatment of Non-Hodgkin Lymphoma That Provides a Longer Duration of Response than Auristatin-Based ADCs in Preclinical Models. Mol Cancer Ther. 2021 Feb;20(2):340-346.
Ref 17 Axcynsis therapeutics product pipeline
Ref 18 The B7-H3-Targeting Antibody-Drug Conjugate m276-SL-PBD Is Potently Effective Against Pediatric Cancer Preclinical Solid Tumor Models. Clin Cancer Res. 2021 May 15;27(10):2938-2946. doi: 10.1158/1078-0432.CCR-20-4221. Epub 2021 Feb 22.
Ref 19 ADC review: basic information about KTN0182A.
Ref 20 EV20/NMS-P945, a Novel Thienoindole Based Antibody-Drug Conjugate Targeting HER-3 for Solid Tumors. Pharmaceutics. 2021 Apr 2;13(4):483. doi: 10.3390/pharmaceutics13040483.
Ref 21 Enzymatic glycan remodeling-metal free click (GlycoConnect) provides homogenous antibody-drug conjugates with improved stability and therapeutic index without sequence engineering. MAbs. 2022 Jan-Dec;14(1):2078466.
Ref 22 BN 80245: An E-ring modified camptothecin with potent antiproliferative and topoisomerase I inhibitory activities. Bioorg Med Chem Lett. 1997;7(17):2235-2238.
Ref 23 Promiximab-duocarmycin, a new CD56 antibody-drug conjugates, is highly efficacious in small cell lung cancer xenograft models. Oncotarget. 2017 Dec 26;9(4):5197-5207. doi: 10.18632/oncotarget.23708. eCollection 2018 Jan 12.
Ref 24 1-(chloromethyl)-2,3-dihydro-1h-benzo[e]indole dimer antibody-drug conjugate compounds, and methods of use and treatment.
Ref 25 Uncialamycin-based antibody-drug conjugates: Unique enediyne ADCs exhibiting bystander killing effect. Proc Natl Acad Sci U S A. 2021 Jun 22;118(25):e2107042118. doi: 10.1073/pnas.2107042118.
Ref 26 Introduction to basic information on recombinant humanized anti-EGFR mAb-DUO-5 conjugate(Zova Biotherapeutics/Zhejiang Hisun Pharmaceutical).
Ref 27 The novel CD19-targeting antibody-drug conjugate huB4-DGN462 shows improved anti-tumor activity compared to SAR3419 in CD19-positive lymphoma and leukemia models. Haematologica. 2019 Aug;104(8):1633-1639. doi: 10.3324/haematol.2018.211011. Epub 2019 Feb 7.
Ref 28 Synthesis and biological evaluation of antibody conjugates of phosphate prodrugs of cytotoxic DNA alkylators for the targeted treatment of cancer. J Med Chem. 2012 Jan 26;55(2):766-82.
Ref 29 Introduction to basic information on anti-B4 monoclonal antibody-DC1 conjugate (Anti-B4-DC1).
Ref 30 Introduction to basic information on ADC drug REGN3124-PBD.
Ref 31 CD25-targeted antibody-drug conjugate depletes regulatory T cells and eliminates established syngeneic tumors via antitumor immunity. J Immunother Cancer. 2020 Sep;8(2):e000860. doi: 10.1136/jitc-2020-000860.
Ref 32 Preclinical activity of hLL2-PBD, a novel anti-CD22 antibody-pyrrolobenzodiazepine (PBD) conjugate in models of non-Hodgkin lymphoma. Cancer Res (2015) 75 (15_Supplement): 637.
Ref 33 Preclinical evaluation of a GFRA1 targeted antibody-drug conjugate in breast cancer. Oncotarget. 2018 May 1;9(33):22960-22975. doi: 10.18632/oncotarget.25160. eCollection 2018 May 1.
Ref 34 Preclinical Evaluation of MEDI0641, a Pyrrolobenzodiazepine-Conjugated Antibody-Drug Conjugate Targeting 5T4. Mol Cancer Ther. 2017 Aug;16(8):1576-1587. doi: 10.1158/1535-7163.MCT-16-0825. Epub 2017 May 18.
Ref 35 A novel enediyne-integrated antibody-drug conjugate shows promising antitumor efficacy against CD30(+) lymphomas. Mol Oncol. 2018 Mar;12(3):339-355. doi: 10.1002/1878-0261.12166. Epub 2018 Jan 26.
Ref 36 Nanovalent pharmaceuticals product pipeline
Ref 37 Development of Highly Optimized Antibody-Drug Conjugates against CD33 and CD123 for Acute Myeloid Leukemia. Clin Cancer Res. 2021 Jan 15;27(2):622-631. doi: 10.1158/1078-0432.CCR-20-2149. Epub 2020 Nov 4.
Ref 38 Enhancement of the selectivity and antitumor efficacy of a CC-1065 analogue through immunoconjugate formation. Cancer Res. 1995 Sep 15;55(18):4079-84.
Ref 39 Pharmacokinetics and tissue distribution of cisplatin and conjugates of cisplatin with carboxymethyldextran and A5B7 monoclonal antibody in CD1 mice. J Pharm Sci. 1997 Dec;86(12):1478-83. doi: 10.1021/js960282u.
Ref 40 Pyxis oncology presents preclinical data and details on antibody-drug conjugate candidates supporting therapeutic potential
Ref 41 Generation and preclinical characterization of CD123-CPI antibody-drug conjugate (ADC). Cancer Res (2018) 78 (13_Supplement): 935.
Ref 42 CLT030, a leukemic stem cell-targeting CLL1 antibody-drug conjugate for treatment of acute myeloid leukemia. Blood Adv. 2018 Jul 24;2(14):1738-1749. doi: 10.1182/bloodadvances.2018020107.
Ref 43 In Vivo Activation of Duocarmycin-Antibody Conjugates by Near-Infrared Light. ACS Cent Sci. 2017 Apr 26;3(4):329-337. doi: 10.1021/acscentsci.7b00026. Epub 2017 Feb 24.
Ref 44 Bispecific anti-mPDGFR x cotinine scFv-C()-scFv fusion protein and cotinine-duocarmycin can form antibody-drug conjugate-like complexes that exert cytotoxicity against mPDGFR expressing cells. Methods. 2019 Feb 1;154:125-135. doi: 10.1016/j.ymeth.2018.10.002. Epub 2018 Oct 4.
Ref 45 Development of novel anti-CD19 antibody-drug conjugates for B-cell lymphoma treatment. Int Immunopharmacol. 2018 Sep;62:299-308. doi: 10.1016/j.intimp.2018.06.034. Epub 2018 Jul 23.
Ref 46 Duocarmycin-based antibody-drug conjugates as an emerging biotherapeutic entity for targeted cancer therapy: Pharmaceutical strategy and clinical progress. Drug Discov Today. 2021 Aug;26(8):1857-1874. doi: 10.1016/j.drudis.2021.06.012. Epub 2021 Jul 3.
Ref 47 Targeted clearance of senescent cells using an antibody-drug conjugate against a specific membrane marker. Sci Rep. 2021 Oct 13;11(1):20358. doi: 10.1038/s41598-021-99852-2.
Ref 48 Generation of a novel Antibody-Drug Conjugate targeting endosialin: potent and durable antitumor response in sarcoma. Oncotarget. 2017 Jul 22;8(36):60368-60377. doi: 10.18632/oncotarget.19499. eCollection 2017 Sep 1.
Ref 49 Glypican-3-Specific Antibody Drug Conjugates Targeting Hepatocellular Carcinoma. Hepatology. 2019 Aug;70(2):563-576. doi: 10.1002/hep.30326. Epub 2019 Feb 19.
Ref 50 Therapeutic efficacy of a novel humanized antibody-drug conjugate recognizing plexin-semaphorin-integrin domain in the RON receptor for targeted cancer therapy. J Immunother Cancer. 2019 Sep 13;7(1):250. doi: 10.1186/s40425-019-0732-8.
Ref 51 An antibody-drug conjugate targeting GPR56 demonstrates efficacy in preclinical models of colorectal cancer. Br J Cancer. 2023 Apr;128(8):1592-1602. doi: 10.1038/s41416-023-02192-3. Epub 2023 Feb 9.
Ref 52 Antitumor activity of a 5T4 targeting antibody drug conjugate with a novel payload derived from MMAF via C-Lock linker. Cancer Med. 2019 Apr;8(4):1793-1805. doi: 10.1002/cam4.2066. Epub 2019 Mar 7.
Ref 53 Introduction to basic information on ADC drug adalimumab fosimdesonide.
Ref 54 cIRCR201-dPBD, a Novel Pyrrolobenzodiazepine Dimer-Containing Site-Specific Antibody-Drug Conjugate Targeting c-Met Overexpression Tumors. ACS Omega. 2020 Sep 29;5(40):25798-25809. doi: 10.1021/acsomega.0c03102.
Ref 55 Inhibition of human tumor xenograft growth in nude mice by a conjugate of monoclonal antibody LA22 to epidermal growth factor receptor with anti-tumor antibiotics mitomycin C. Biochem Biophys Res Commun. 2006 Oct 20;349(2):816-24. doi: 10.1016/j.bbrc.2006.08.114. Epub 2006 Aug 28.
Ref 56 Antibody-Drug Conjugates Derived from Cytotoxic seco-CBI-Dimer Payloads Are Highly Efficacious in Xenograft Models and Form Protein Adducts In Vivo. Bioconjug Chem. 2019 May 15;30(5):1356-1370. doi: 10.1021/acs.bioconjchem.9b00133. Epub 2019 Apr 22.
Ref 57 ICOS is widely expressed in cutaneous T-cell lymphoma, and its targeting promotes potent killing of malignant cells. Blood Adv. 2020 Oct 27;4(20):5203-5214. doi: 10.1182/bloodadvances.2020002395.
Ref 58 Adagene and ADC therapeutics announce SAFEbody license agreement; 2019
Ref 59 Internalization of Foldamer-Based DNA Mimics through a Site-Specific Antibody Conjugate to Target HER2-Positive Cancer Cells. Pharmaceuticals (Basel). 2021 Jun 28;14(7):624. doi: 10.3390/ph14070624.
Ref 60 Preclinical development of ADCT-211, a novel pyrrolobenzodiazepine dimer-based antibody-drug conjugate targeting solid tumors expressing IL13RA2. Cancer Res (2023) 83 (7_Supplement): 1604.
Ref 61 Preclinical development of ADCT-212, a PSMA-targeted antibody-drug conjugate employing the pyrrolobenzodiazepine dimer SG2000 for PSMA-expressing cancers. Cancer Res (2023) 83 (7_Supplement): 2638.
Ref 62 Design considerations of an IL13R2 antibody-drug conjugate for diffuse intrinsic pontine glioma. Acta Neuropathol Commun. 2021 May 17;9(1):88. doi: 10.1186/s40478-021-01184-9.
Ref 63 Design, Synthesis, and Structure-Activity Relationships of Novel Tetrahydroisoquinolino Benzodiazepine Dimer Antitumor Agents and Their Application in Antibody-Drug Conjugates. J Med Chem. 2020 Nov 25;63(22):13913-13950. doi: 10.1021/acs.jmedchem.0c01385.
Ref 64 IKS01, a next generation antibody drug conjugate, shows target-dependent efficacy in a platinum-resistant tumor model with low levels of folate receptor alpha expression. Mol Cancer Ther (2019) 18 (12_Supplement): C023.
Ref 65 ADC review IPH43
Ref 66 Novel antibody conjugates and uses thereof; 2014-08-28.
Ref 67 Anti-huLRRC15 antibody drug conjugates and methods for their use. 2017-06-08
Ref 68 ANTI-cMet antibody drug conjugates and methods for their use; 2017-11-23.
Ref 69 Generation of DAR1 Antibody-Drug Conjugates for Ultrapotent Payloads Using Tailored GlycoConnect Technology. Bioconjug Chem. 2023 Mar 15;34(3):538-548. doi: 10.1021/acs.bioconjchem.2c00611. Epub 2023 Mar 1.
Ref 70 New Senolysis Approach via Antibody-Drug Conjugate Targeting of the Senescent Cell Marker Apolipoprotein D for Skin Rejuvenation. Int J Mol Sci. 2023 Mar 20;24(6):5857. doi: 10.3390/ijms24065857.
Ref 71 Anti-tumor activity of antibody drug conjugate targeting aspartate--hydroxylase in pancreatic ductal adenocarcinoma. Cancer Lett. 2019 May 1;449:87-98. doi: 10.1016/j.canlet.2019.02.006. Epub 2019 Feb 12.
Ref 72 APOMAB Antibody-Drug Conjugates Targeting Dead Tumor Cells are Effective In Vivo. Mol Cancer Ther. 2019 Feb;18(2):335-345. doi: 10.1158/1535-7163.MCT-18-0842. Epub 2018 Nov 9.
Ref 73 Aptamer-Directed Conjugation of DNA to Therapeutic Antibodies. Bioconjug Chem. 2019 Aug 21;30(8):2127-2135. doi: 10.1021/acs.bioconjchem.9b00363. Epub 2019 Jul 12.
Ref 74 Aryl Sulfate is a Useful Motif for Conjugating and Releasing Phenolic Molecules: Sulfur Fluorine Exchange Click Chemistry Enables Discovery of Ortho-Hydroxy-Protected Aryl Sulfate Linker. Bioconjug Chem. 2019 Jul 17;30(7):1957-1968. doi: 10.1021/acs.bioconjchem.9b00340. Epub 2019 Jun 28.
Ref 75 Antibody fragment-conjugated gemcitabine and paclitaxel-based liposome for effective therapeutic efficacy in pancreatic cancer. Mater Sci Eng C Mater Biol Appl. 2018 Aug 1;89:328-335. doi: 10.1016/j.msec.2018.04.011. Epub 2018 Apr 11.
Ref 76 Novel b7-h3 binding molecules, antibody drug conjugates thereof and methods of use thereof; 2017-10-19.
Ref 77 Phosphate based linkers for intracellular delivery of drug conjugates; 2015-10-08.
Ref 78 Pyrrolobenzodiazepines and conjugates thereof; 2013-04-18.
Ref 79 High-Affinity Human Anti-c-Met IgG Conjugated to Oxaliplatin as Targeted Chemotherapy for Hepatocellular Carcinoma. Front Oncol. 2019 Aug 2;9:717. doi: 10.3389/fonc.2019.00717. eCollection 2019.
Ref 80 Internal enhancement of DNA damage by a novel bispecific antibody-drug conjugate-like therapeutics via blockage of mTOR and PD-L1 signal pathways in pancreatic cancer. Cancer Med. 2019 Feb;8(2):643-655. doi: 10.1002/cam4.1974. Epub 2019 Jan 25.
Ref 81 Natural Product Bis-Intercalator Depsipeptides as a New Class of Payloads for Antibody-Drug Conjugates. Bioconjug Chem. 2019 Jan 16;30(1):200-209. doi: 10.1021/acs.bioconjchem.8b00843. Epub 2018 Dec 13.
Ref 82 Optimizing Lysosomal Activation of Antibody-Drug Conjugates (ADCs) by Incorporation of Novel Cleavable Dipeptide Linkers. Mol Pharm. 2019 Dec 2;16(12):4817-4825. doi: 10.1021/acs.molpharmaceut.9b00696. Epub 2019 Oct 29.
Ref 83 A single dose of antibody-drug conjugate cures a stage 1 model of African trypanosomiasis. PLoS Negl Trop Dis. 2019 May 23;13(5):e0007373. doi: 10.1371/journal.pntd.0007373. eCollection 2019 May.
Ref 84 An antibody-drug conjugate directed to the ALK receptor demonstrates efficacy in preclinical models of neuroblastoma. Sci Transl Med. 2019 Mar 13;11(483):eaau9732. doi: 10.1126/scitranslmed.aau9732.
Ref 85 An Anti-CLL-1 Antibody-Drug Conjugate for the Treatment of Acute Myeloid Leukemia. Clin Cancer Res. 2019 Feb 15;25(4):1358-1368. doi: 10.1158/1078-0432.CCR-18-0333. Epub 2018 Jun 29.
Ref 86 Intratumoral Payload Concentration Correlates with the Activity of Antibody-Drug Conjugates. Mol Cancer Ther. 2018 Mar;17(3):677-685. doi: 10.1158/1535-7163.MCT-17-0697. Epub 2018 Jan 18.
Ref 87 Antibody-Drug Conjugates Derived from Cytotoxic seco-CBI-Dimer Payloads Are Highly Efficacious in Xenograft Models and Form Protein Adducts In Vivo. Bioconjug Chem. 2019 May 15;30(5):1356-1370. doi: 10.1021/acs.bioconjchem.9b00133. Epub 2019 Apr 22.
Ref 88 TR1801-ADC: a highly potent cMet antibody-drug conjugate with high activity in patient-derived xenograft models of solid tumors. Mol Oncol. 2020 Jan;14(1):54-68. doi: 10.1002/1878-0261.12600. Epub 2019 Dec 3.
Ref 89 Targeting and Efficacy of Novel mAb806-Antibody-Drug Conjugates in Malignant Mesothelioma. Pharmaceuticals (Basel). 2020 Oct 2;13(10):289. doi: 10.3390/ph13100289.
Ref 90 Synthesis of Highly Potent N-10 Amino-Linked DNA-Alkylating Indolinobenzodiazepine Antibody-Drug Conjugates (ADCs). ACS Med Chem Lett. 2019 Jul 22;10(8):1211-1215. doi: 10.1021/acsmedchemlett.9b00254. eCollection 2019 Aug 8.
Ref 91 Bcma monoclonal antibody-drug conjugate.
Ref 92 Site-specific conjugation of linker drugs to antibodies and resulting adcs.
Ref 93 Covalent linkers in antibody-drug conjugates and methods of making and using the same.
Ref 94 Anti-CD45 PBD-based antibody-drug conjugates are effective targeted conditioning agents for gene therapy and stem cell transplant
Ref 95 Antibody-Drug Conjugates to Treat Bacterial Biofilms via Targeting and Extracellular Drug Release
Ref 96 Harnessing acylhydrazone-oxime exchange reaction to achieve diverse synthesis of glycosite-specific antibody-drug conjugates
Ref 97 Fertility-preserving myeloablative conditioning using single-dose CD117 antibody-drug conjugate in a rhesus gene therapy model
Ref 98 Effective eradication of acute myeloid leukemia stem cells with FLT3-directed antibody-drug conjugates
Ref 99 TRBC1-targeting antibody-drug conjugates for the treatment of T cell cancers
Ref 100 KK2845, a PBD dimer-containing antibody-drug conjugate targeting TIM-3-expressing AML
Ref 101 QLS5132, a highly selective anti-CLDN6 ADC with broader therapeutic window
Ref 102 AM E3-SG3249, a first-in-class α-CRLF2 antibody-drug conjugate for the treatment of CRLF2-rearranged Ph-like B-ALL
Ref 103 BCMA monoclonal antibody-drug conjugate
Ref 104 Non-linear self-immolative linkers and conjugates thereof
Ref 105 JP2024177330A5 - Google Patents
Ref 106 Anti-ROR1 antibodies and antibody conjugates, compositions comprising Anti-ROR1 antibodies or antibody conjugates, and methods of making and using Anti-ROR1 antibodies and antibody conjugates
Ref 107 Anti-ROR1 antibodies and antibody conjugates, compositions comprising Anti-ROR1 antibodies or antibody conjugates, and methods of making and using Anti-ROR1 antibodies and antibody conjugates
Ref 108 TRBC targeting antibody-drug conjugates
Ref 109 Antibody-drug conjugates containing an anti-mesothelin antibody and uses thereof
Ref 110 Anti-IL-13Rα2 conjugates
Ref 111 Antibody-drug complexes containing anti-CD138 antibodies
Ref 112 Transplantation after CD45-ADC corrects Rag1 immunodeficiency in congenic and haploidentical settings